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ABSTRACT OF THE DISSERTATION
The Role of the Pituitary-Adrenal Axis in G-CSF Therapy after
Neonatal Hypoxia-Ischemia
by
Mélissa Stéphanie Charles
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2012
Dr. Jiping Tang, Chairperson
Several reports indicate that the activity of the hypothalamic-pituitary-adrenal
axis (HPA) as measured by the increased level of adrenocorticotropic hormone (ACTH),
and corticosterone is increased after a brain insult. These hormones are the effectors
secreted respectively by the pituitary and adrenal glands. It has been shown that the
down-regulation of corticosterone levels can improve detrimental outcomes associated
with ischemic brain injuries. Neonatal hypoxia-ischemia (HI) is a devastating perinatal
event with a grim prognosis and limited therapeutic strategies. In recent studies,
granulocyte-colony stimulating factor (G-CSF) has shown promise in neonatal HI
investigations by improving neuromotor function and reducing apoptosis in the brain.
Furthermore, G-CSF is shown in the naïve rat to regulate hormones of the HPA axis.
Therefore we hypothesized that G-CSF may in part confer its neuroprotective properties
by influencing the pituitary-adrenal response after neonatal HI. To test our hypothesis,
metyrapone was administered to inhibit the release of rodent specific glucocorticoid,
corticosterone, at the adrenal level. Dexamethasone, a synthetic glucocorticoid, was
administered to agonize the effects of corticosterone. Following the Rice-Vannucci
model, seven-day old rats (P7) were subjected to unilateral carotid ligation followed by
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2.5 hours of hypoxia. Our results show that both G-CSF and metyrapone significantly
reduced infarct volume via anti-apoptotic properties but lost its protective effect when
combined with dexamethasone. Additionally, G-CSF suppressed the increase of
corticosterone in the blood after HI. To investigate the mechanism by which G-CSF
modulated corticosterone synthesis, we evaluated its effect in adrenal cortical cells in
vitro. Our results indicate that G-CSF activated the JAK/PI3K/Akt/PDE3B pathway,
which in turn inhibited corticosterone synthesis. The inhibitors of JAK/PI3K/PDE3B
respectively Tyrphostin AG490, LY-294002, and 3-isobutyl-1methylxanthine reversed
the inhibitory effect of G-CSF on corticosterone synthesis. We report that G-CSF was
neuroprotective in neonatal HI by reducing infarct volume, by suppressing the HIinduced increase of the Bax/Bcl-2 ratio, and by decreasing corticosterone at the adrenal
level via the JAK/PI3K/PDE3B pathway. Metyrapone was able to confer similar
neuroprotection as G-CSF while dexamethasone reversed the effects of G-CSF. In
conclusion, we show that reducing corticosterone was neuroprotective after neonatal HI,
which can be achieved by administering G-CSF.
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CHAPTER ONE
INTRODUCTION
Neonatal Hypoxia Ischemia
Neonatal hypoxia-ischemia (HI) is a major public health concern affecting both
term and preterm infants. It is characterized by exposure to low oxygen (hypoxia) and
decreased blood flow (ischemia) before, during, or after labor (Covey and Levison,
2006). This event is clinically defined as asphyxia and diagnosed as hypoxic-ischemic
encephalopathy (Zanelli et al, 2009). This clinical diagnosis is a tragic occurrence that
will afflict the infants with lifelong complications. For instance, inveterate conditions
such as cerebral palsy, mental retardation, and epilepsy are part of the grim prognosis, to
name a few (Hill and Volpe, 1989). Undoubtedly, this clinical event is increasingly
becoming burdensome not only for the patients, but also for the families, and
communities that care for them. This alarming problem is a financial issue as much as it
is a health complication. The lifelong projected costs for cerebral palsy alone are
estimated at $11.5 billion dollars in the United States (Derrick et al, 2007). For this
reason it has become imperative to investigate the causes and prevalence of this particular
condition in the population. Thereupon, one can establish how to approach an issue that
transcends medical science, public health, and the economy.
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Epidemiology
HI is a major contributor to global child mortality and morbidity (Wachtel et al,
2011). HI has an overall incidence of 1-8 cases per 1000 births affecting 60% of preterm
infants (Vannucci et al, 1999; Zanelli et al, 2009). With the increasing rate of premature
births in the United States (Callaghan et al, 2006), the projected costs associated with HI
are bound to increase. The chronic complications induced by HI affect a staggering 80%
of survivors (Derrick et al, 2007; Zanelli et al, 2009). Because premature infants have an
underdeveloped cerebral circulation, a high density of excitatory neurons, and more
vulnerable neurons to reactive oxygen species and reactive nitrogen species, they
experience a more severe injury than full-term infants (Takeoka et al, 2002). HI injury is
caused by a cascade of cytotoxic, oxidative and inflammatory stresses leading to brain
infarct, cerebral edema and neurological deficits (Vannucci et al, 2000).

Pathophysiology of HI
The development of brain injury in the immature brain can be divided in two
phases; acute phase, and the reperfusion (delayed) phase (Lai and Yang, 2011). The
magnitude of the damage depends on the duration of the insult, the age of the infant,
reperfusion injury, and apoptosis (Zanelli et al, 2011). The initial effect of the depleted
oxygen concentration and reduced blood flow to the brain is energy failure (Vannucci et
al, 2005). The deprivation of glucose and the oxygen supply forces the cells to generate
energy via glycolysis through anaerobic respiration. This increases lactate production and
creates an acidic environment for the cells in the central nervous system (CNS) (Verklan,
2009). The deleterious effect of this primary energy failure impairs vascular
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autoregulation, and the low pH halts the activity of cellular enzymes (Johnston et al,
2001). The sodium potassium ATP pump will then begin to fail, and cause an
intracellular accumulation of sodium and calcium ions (Barks and Silverstein, 1992). The
intracellular accumulation of these ions will cause the neurons to depolarize and release a
large amount of excitatory amino acid including glutamate (Wyatt et al, 1989). During
the reperfusion period, free radical damage will be initiated and the reactive oxygen
species will combine with the synthesized nitric oxide from glutamate receptor activation
to form toxic oxidants (Zanelli et al, 2011; Lai and Yang, 2011; Pacher et al, 2007).
Calcium ion accumulation will activate a series of enzymes including endonucleases,
proteases and phospholipases that will damage and degrade protein, and DNA
(Ankarcrona et al, 1995). The latter will initiate the apoptotic and necrotic cascade which
will cause the cells to die. The releasing of pro-inflammatory cytokines by resident
immune cells of the CNS, and peripheral immune cells extravasating to the area of injury
will initiate the inflammatory response (Iadecola and Anrather, 2011; Ferriero, 2004). All
of which contribute to cerebral edema, subsequently leading to cell death. Early cell
death is typically necrotic and the continuum will make delayed cell death apoptotic
(Northington et al, 2001). Apoptosis will occur over days as a result of a less severe
insult, thus being a potential therapeutic target (Varklan, 2009). The penumbra, the area
surrounding the ischemic necrotic core, is not exposed to the same intensity of energy
failure placing these neurons in a critical stage where they can be recovered (Nakajima et
al, 2000; Pulera et al, 1998). Nevertheless, if these neurons are not rescued, within hours
the damage will eventually become irreversible as energy failure propagates towards the
rescuable cells in the penumbra.
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Clinical Presentation
Within the first hours after the injury, the neonate will be unresponsive to sensory
input, and have a low level of consciousness (Volpe, 2003; Sarnat and Sarnat, 1976).
Hypotonia, pupillary response may be intact depending on the severity and propagation
of brain injury. The infant will also exhibit abnormal respiratory patterns (Ferriero,
2004). In severe cases, 50-60% of those affected will have seizures. Subtle seizures can
be observed as rowing, bicycling, sucking movements, and apnea (Verklan, 2009).
Eventually, in the cases of moderate-severe injury, within 24-72 hours the infant will
succumb and deteriorate (Volpe, 2003). Respiratory failure, deep stupor, and fixed pupils
may occur prior or immediately before death (ibid; Varklan, 2009).

Therapeutic Options
In spite of the critical mortality, morbidity, and socio-economic hardship
accompanied with HI, therapeutic avenues are still lacking. Various anticonvulsants,
hypothermic treatments, and fluid and electrolytes management constitute current clinical
treatment, however, they have proven only some degree of success (Koenisgsberger,
2000; Zanelli et al, 2009). Due to the complexity of timing, time-window of experimental
therapeutic options, and a lack of thorough mechanistic studies, it has become crucial to
investigate novel and effective treatment plans for HI. Since the body’s compensatory
response often contributes to the injury, it has become increasingly imperative to
understand the physiological cascades that preclude the pathophysiological sequelae. For
example, one physiological response that is known to exacerbate injury, is the increase of
the activity of the hypothalamic-pituitary-adrenal axis.
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Hypothalamic-Pituitary-Adrenal (HPA) Axis
The HPA axis is an intrinsic neuroendocrine regulatory system found in
vertebrates that allows the organism to respond and adapt to internal or external stressors
(Tsigos and Chrousos, 2002). It is a system that helps the organism maintain homeostasis
particularly after a challenge and is vital for supporting normal physiological functioning
(Kudielka and Kirschbaum, 2005). For the interest of clarity, we chose a simplified
definition of stress as internal or external stimuli that can disrupt the biological
equilibrium. This can include a cerebrovascular event such as HI (Krugers et al, 2000;
Fassbender et al, 1994).

Anatomy of the HPA Axis
The brain circuits that initiate the stress response start in the paraventricular nuclei
(PVN) of the hypothalamus (Chrousos, 1992). The parvocellular corticotropin-releasing
hormone (CRH) and arginine-vasopressin are secreted and released in the hypophyseal
portal system where it can act on the anterior lobe of the pituitary gland (Lamberts et al,
1984; Vale et al, 1981). The PVN has neurons that project to the median eminence where
a hypophyseal system of capillaries transports CRH in the vascularized anterior pituitary
gland (Turnbull and Rivier, 1999). CRH is a 41-amino acid peptide that drives the
adrenocorticotropic hormone (ACTH) secretion and synthesis (Vale et al, 1981).
Arginine-vasopressin has little secretagogue activity, it acts as a synergistic factor for
CRH activity at the pituitary level. In normal conditions, when there is no stress, CRH is
released in a pulsatile fashion resulting in a diurnal rhythm peaking in the early hours of
the morning and nadir during the first few hours of sleep (Turnbull and River, 1999;
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Tsigos and Chrousos, 2002; Horrocks et al, 1990). The circadian changes are influenced
by a variety of factors, such as lighting, activity, and stress. CRH binds to its G-protein
coupled receptor on the corticotrope cells of the anterior pituitary lobe to stimulate the
synthesis of proopiomelanocortin (POMC), the ACTH precursor (Turnbull and Rivier,
1996; Turnbull and Rivier, 1999). ACTH is then secreted in the systemic circulation, and
binds to its receptor, also G-protein coupled, in the zona fasciculata of the adrenal cortex.
The downstream signaling pathway of ACTH receptor activation leads to the synthesis
and secretion of glucocorticoids in the blood (Ottenweller and Meier, 1982). In humans
the major glucocorticoid is cortisol, and in rodents it is corticosterone. Glucocorticoids
are the final effectors of the HPA axis that control a variety of physiological functions.
These include the immune response, cardiac output, and metabolism, all of which
participate in maintaining homeostasis (Pratt, 1990). Glucocorticoids also interact with
the pituitary gland and the hypothalamus in the classical feedback endocrine system, to
terminate the stress response by inhibiting the synthesis of CRH and ACTH.

Steroidogenesis
Glucocorticoids are products of steroidogenesis, the biological process where
steroids are generated from cholesterol. When ACTH binds to its receptor the
melanocortin receptor-2, a G-protein coupled receptor, it activates adenylyl cyclase,
which will increase cyclic (cAMP) (Mountjoy et al, 1992; Liakos et al, 1998). The
increase of intracellular cAMP will activate protein kinase A (PKA), which will release
its catalytic subunit and activate the cAMP response element binding protein (CREB)
(Sun et al, 2003). CREB will then activate the transcription, and translation of the
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steroidogenic acute regulatory (Star) protein responsible for the rate-limiting step of
steroidogenesis: transporting cholesterol from the outer to the inner mitochondrial
membrane (Manna et al, 2002; Rainey et al, 2004). Once in the mitochondria, the
cholesterol is cleaved by cytochrome P450 enzyme (Privalle et al, 1983). Through a
series of hydroxylation mediated by enzymes located in the smooth endoplasmic
reticulum and mitochondria, cortisol and corticosterone are synthesized. Once secreted in
the circulatory system, it then exerts its physiological function by activating its
ubiquitous glucocorticoid cytoplasmic receptor, a 94 kDa polypeptide (Smith and Toft,
1993; Pratt, 1990).

Glucocorticoid Functions
The binding of glucocorticoids to the glucocorticoid receptor will cause it to
phosphorylate and translocate to the nucleus, where it interacts with glucocorticoid
responsive elements (Pratt, 1990). This will lead to the repression or activation,
transcription, and translation of genes, which will cause pleiotropic physiological effects
(Scheinmann et al, 1995). The effects of glucocorticoids target metabolism, arousal,
cognition, development, and the immune system.
Glucocorticoids, as the name suggests, is involved in glucose metabolism
(Chrousos, 2000). Extra-hepatical amino acids are mobilized as a response to increased
circulating glucocorticoids and used as substrate for gluconeogenesis (Tsigos et al, 1997).
The increase of glucocorticoids will inhibit glucose uptake and induce insulin resistance
(Tsigos and Chrousos, 2002). Chronic activation of stress will eventually increase
visceral adiposity, decrease lean body mass, and suppress osteoblastic activity (ibid).
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These effects can become clinically problematic for diseased patients, who may be
subjected to a stressor whether physiological or emotional.
Events associated with strong emotions or deemed stressful are often clearly
remembered by the subjects who experienced it. This “flash bulb” memory of the event is
attributed to the action of glucocorticoid on hippocampus, amygdala, and frontal lobes
(Cahill and McGaugh, 1999). The effect of glucocorticoid on cognitive performance and
memory is substantiated by extensive animal research (ibid). However the effects of
glucocorticoid follow an inverted-U-shape dose response curve (Lupien et al, 2007). Too
much glucocorticoid and too little will lead to poor memory consolidation, and will
inhibit the retrieval of previously stored information (de Quervain et al, 1998).
Glucocorticoids are also critical for lung maturation and development (Olson et
al, 1979). This rings particularly true for preterm infants. Premature babies do not have
adequate surfactant in their lungs, which is necessary to decrease the air-liquid surface
tension interface (Bolt et al, 2001). Due to this insufficiency, these infants are at
increased risk for respiratory distress syndrome (Crowley, 2000). If the respiratory
distress syndrome is treated with long term mechanical ventilation it can lead to
bronchopulmunary dysplasia (Northway et al, 1967). These conditions are treated with
synthetic glucocorticoids to increase surfactant production. However, as previously
mentioned, glucocorticoids increase glucose synthesis, and reduce its uptake, therefore
some side effects include hyperglycemia, hypertension, inhibition of somatic growth and
a myriad of other physiological changes (Halliday and Ehrenkranz, 2000). Although
beneficial for lung maturation, the detrimental effects of chronic administration of
glucocorticoids may outweigh the benefits.
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In addition to their effects on memory, glucose metabolism, and development,
glucocorticoids are well characterized for their immune suppressing capabilities
(Franchimont, 2004). Glucocorticoids have been in use for over half a century to treat
inflammatory and autoimmune diseases (ibid). This class of hormones suppresses cellular
immunity, and promotes humoral immunity. Although the anti-inflammatory effects of
glucocorticoids are reported in the peripheral system, this effect does not translate to the
CNS. In fact, it is reported to exacerbate injury and increase inflammation after a
neuronal insult (Sorrells et al, 2009). The activity of HPA axis after a cerebrovascular
event, and the effect of glucocorticoid after such a stressor do not align with its antiinflammatory properties.

Glucocorticoids and Brain Injury
Recent advances reveal that glucocorticoids are detrimental to neuronal repair
and survival after an insult (Sapolsky, 1999; Dinkel et al, 2003). Notably, it is shown to
increase pro-inflammatory cytokines, induce apoptosis, and increase neurotoxicity (Caso
et al, 2007; Macpherson et al, 2005; Zoloaga et al, 2011; Arya et al, 2006). It was further
demonstrated that treatment with the rodent specific glucocorticoid, corticosterone,
worsened hippocampal neurons after global ischemia (Sapolsky and Pulsinelli, 1985). It
appears that glucocorticoids have opposite effects in the CNS. This raises the question
whether these reports found in adult studies are true to neonatal models of brain injuries.
Studies have shown that administering a synthetic glucocorticoid, dexamethasone,
before a hypoxic-ischemic event in neonatal rats is beneficial (Feng et al, 2011; Ikeda et
al, 2005; Felszeghy et al, 2004; Ekert et al, 1997; Tuor et al, 1996). However, these
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studies overlook that most incidences of HI can occur in utero, thus making the time of
occurrence difficult to detect (Perlman, 2006). Particularly since these studies suggest
that the protective effects only are seen when dexamethasone is administered at least 6
hours prior to the insult. Because synthetic glucocorticoid administration has not
previously been investigated in neonatal HI after the insult, it is highly probable that posttreatment, may result in hyperglycemia, hypertension, and decrease of somatic growth as
reported in preterm infants treated for bronchopulmunary dysplasia (Halliday and
Ehrenkranz, 2000). Also, since glucocorticoids are the last effector of the HPA axis it
may be likely that agonizing an already stressed HPA with dexamethasone could prove
detrimental.
The HPA activity is increased after a cerebrovascular event. Numerous studies
focusing on the pituitary-adrenal response show that ACTH and corticosterone is
upregulated after HI and that inhibiting glucocorticoid synthesis can reduce brain damage
(Krugers et al, 1998; Krugers et al, 2000). Clinical studies have also shown that
glucocorticoids reduce cerebral cortical grey matter volume (Murphy et al, 2001), and
impair long-term neuromotor and cognitive function (Yeh et al, 2004). Understanding the
implication of the last effector of the HPA axis is clinically paramount since synthetic
glucocorticoids are often administered systemically in premature infants. The hormones
of the HPA axis appear to be beneficial or detrimental within certain confines and
limitations warranting a better understanding of its regulation and modulation. A recent
report showed that a neuroprotective agent widely used in the clinic for hematopoietic
purposes, could modulate the levels of ACTH and corticosterone in naïve adult rats
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(Mucha et al, 2000). This promising neuroprotective drug is granulocyte-colony
stimulating factor (G-CSF).

Granulocyte-Colony Stimulating Factor (G-CSF)
Functions of G-CSF
G-CSF is a glycoprotein with a molecular weight of 19 kDa produced by a wide
range of cells including bone marrow cells, fibroblasts, and endothelial cells (Demetri
and Griffin, 1991). It is a hematopoietic growth factor that initiates proliferation,
differentiation, and proliferation of granulocytes (Nicola, 1990). The G-CSF protein is
encoded by a single gene located on chromosome 17 q11-12 (Solaroglu et al, 2006; Le
Beau et al, 1987). G-CSF confers its action by activating its receptor (G-CSF-R), a
transmembrane protein of the class I cytokine receptor family (Bazan, 1990). The
receptor has an immunoglobulin-like domain, a cytokine receptor-homologous domain
and three fibronectin type III domains in the extracellular region (Fukunaga et al, 1991).
The downstream signaling pathway of G-CSF-R activation include the Janus Kinase
(JAK)/ signal transducer and activator of transcription (STAT), the Ras/mitogenactivated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K) pathway
(Tian et al, 1994; Shimoda et al, 1997; Ward et al, 2000). G-CSF-R is expressed on a
myriad of cells including those in the CNS; neurons, glial cells, and endothelial cells
(Demetri and Griffin, 1991). The cloning of G-CSF established its clinical application
were it is now commonly used to treat chemotherapy-induced neutropenia (Schneider et
al, 2005; Neidhart et al, 1989). The wide use of G-CSF for hematopoietic recovery has
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made this drug potentially translatable to neurological brain injury, particularly since its
pharmacokinetic profile is well known.

Neuroprotective Capabilities of G-CSF
Numerous studies give account of G-CSF as a neuroprotective agent (Solaroglu et
al, 2006; Schäbitz et al, 2010; Popa-Wagner et al, 2010). It was first investigated in vitro
where it protected neurons from glutamate-induced cell death (Schäbitz et al, 2003).
Furthermore, it was shown to be upregulated in the penumbra after an ischemic insult
(ibid; Kleinschnitz et al, 2004). This suggests that the organism has a compensatory
response to increase endogenous neuroprotective proteins. Other studies using various
models of brain injury reported that G-CSF reduced infarct volume, mortality, brain
edema, and apoptosis (Six et al, 2003; Park et al, 2005; Whalen et al, 2000). It was
postulated that G-CSF may confer its protective properties by increasing neutrophils in
addition to activating its receptor in the CNS. However, reports have shown that the
increase of neutrophils or bone marrow stromal cells do not improve neurological
function after a brain insult (Chopp and Li, 2002; Hudome et al, 1997). Therefore
suggesting that neutrophil increase is not involved in G-CSF induced neuroprotection.
Additionally, it was further demonstrated that 5 daily doses of G-CSF (50 µg/kg)
improved neurological behavior 28 days after ischemia, as measured by cognitive and
sensorimotor tests (Gibson et al. 2005; Fathali et al, 2010). The protective properties of
G-CSF are pleiotropic as it was demonstrated that it could improve neural plasticity and
vascularization, reduce pro-inflammatory cytokines, and protect against excitotoxicity
(Zavala et al, 2002; Schäbitz et al, 2003; Shyu et al, 2004). In light of these observations,
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G-CSF has promising therapeutic potential due to its multimodal effects. Whether these
results translate to the pediatric population is questioned since these studies were mostly
conducted in adults. Although cues are taken from the vast body of literature of adult
ischemic injury, the nature of neonatal injury is substantially different (Vannucci, 2007).
The brain of term infants is susceptible to injury in areas of high metabolic demands, and
high density of excitatory neurons (Takeoka et al, 2002). Preterm infants sustain a more
severe injury because of their underdeveloped circulatory system (ibid). Therefore to
adequately assess the therapeutic potential of G-CSF in the pediatric population,
specifically low birth weight and premature infants, age appropriate animal models are
required.
G-CSF has shown promise in neonatal studies where it protected the brain from
apoptosis, increased development, and improved neurobehavioral outcomes (Yata et al,
2007; Fathali et al, 2010). There is one study conducted by Schlager and colleagues,
which shows that G-CSF did not improve neurobehavioral outcomes or brain injuries
(2011). The contradicting results reported by Schlager and colleagues could be attributed
to their experimental design. They used 4 times the dose reported in previous studies, and
administered the drug 60 hours after the initial insult whereas other studies started
therapy as early as 1 hour after the insult (Yata et al, 2007; Fathali et al, 2010). All things
considered, the dearth of neonatal studies looking at G-CSF after HI indeed shows an
area meriting scientific exploration.
The mechanism of G-CSF action remains to be adequately elucidated. The
evidence that G-CSF may modulate (ACTH) and glucocorticoids in naïve rats (Mucha et
al, 2000) suggests that it has a probable interaction with the neuroendocrine system.
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These hormones are effectors of the HPA axis, which are reported to play a critical role
in ischemic brain injury. Determining if G-CSF regulates these hormones in a neonatal
model with a different HPA response than adults, after a diseased state known to increase
HPA activity warrants much needed examination.

Significance of Studies
The complexity of the neurodevelopmental sequelae of HI necessitates a drug
with multimodal properties. Therefore, to address the limitations clinically observed for
the treatment of HI, we propose to study for the first time the interaction between a
hematopoietic neuroprotective growth factor, G-CSF, with the neuroendocrine pituitaryadrenal activation in a neonatal model of HI brain injury. G-CSF and its mechanistic
properties on the HPA axis have not previously been studied in a neonatal HI model.
Furthermore, the effects of G-CSF on infarct volume have not previously been reported
in neonates. The novel theoretical concept that this study sets forth will challenge the
clinical practice paradigm that administers synthetic glucocorticoids to pre-term neonates
with high propensity to HI complications. Equally important, is the fact that no previous
reports examined the mechanism of G-CSF on steroidogenesis. For this purpose, our
proposed investigation will add fundamental information that may guide future research
in a wide range of directions. Particularly since G-CSF is already in clinical use for
neonatal neutropenia, this compound can feasibly be introduced into practice for neonatal
neuroprotection (Schlager et al, 2011; Kuhn et al, 2009; Carr et al, 2003). Herein lies the
novelty where we aim at investigating the mechanism of G-CSF via the HPA effector
hormone, corticosterone, in a rat neonatal model of HI.
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The supposition that G-CSF may influence glucocorticoid synthesis is highly
probable due to its ability to activate class I cytokine receptors (Aritomi et al, 1999).
Class I cytokine receptors are transmembrane proteins expressed on the surface of cells
including the steroidogenic adrenal cortical cells (Hoggard et al, 1997; Malendowicz et
al, 2003). Studies have shown that class I cytokine receptor ligands, such as leptin, can
inhibit corticosterone synthesis in vitro (Hsu et al, 2006; Salzmann et al, 2004). Because
G-CSF and leptin share sequence homology, we propose that G-CSF may inhibit
glucocorticoid synthesis. No previous reports indicate that the G-CSF receptor is
expressed on adrenal glands; therefore we postulate that its activity is via the cytokine
family receptor. Also, a variety of intracellular cascades activated by G-CSF decrease
apoptotic markers caspase-3 and Bax (Solaroglu et al, 2009); these intracellular cascades
are also regulated by glucocorticoids. Based on this evidence our central hypothesis is
that is that G-CSF will protect the neonatal brain from apoptosis by suppressing the
activity of the pituitary-adrenal response via the activation of its cytokine receptor after
HI.

Approach of Studies
The rationale of this study is that identifying the mechanisms involved in G-CSF
therapy for neonates will extend into adequately designed clinical applications for infants
victimized by HI. We plan to achieve the goal of this study with the following aims
which is summarized in a schematic diagram (Figure1.1).
AIM 1: Evaluate the anti-apoptotic properties of G-CSF via the pituitary-adrenal axis
after neonatal HI.
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Because reports indicate that glucocorticoids can exacerbate apoptosis we
hypothesize that G-CSF reduces brain infarct and does so by inhibiting corticosterone
synthesis.
AIM 2: Determine the mechanism by which G-CSF inhibits corticosterone synthesis in
vitro.
We hypothesize that G-CSF activates class I cytokine receptors on the adrenal
glands which reduces corticosterone. This study will be conducted in well-characterized
rodent Y1 adrenal cortical cells.
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Figure 1.1. Schematic representation of the central hypothesis and specific aims.
Aim 1 as illustrated in blue will investigate the effect of G-CSF on corticosterone
synthesis in vivo after neonatal HI, measure the apoptotic markers in the brain and assess
infarct volume. Aim 2 (black) will study the effect of G-CSF in vitro on corticosterone
synthesis. This aim proposes that G-CSF activates the JAK2/PI3K/Akt/PDE3B signaling
pathway
to
inhibit
corticosterone
synthesis
by
degrading
cAMP.

17

CHAPTER TWO
ROLE OF THE PITUITARY-ADRENAL AXIS IN GRANULOCYTE-COLONY
STIMULATING FACTOR-INDUCED NEUROPROTECTION AGAINST HYPOXIAISCHEMIA IN NEONATAL RATS

Mélissa S. Charlesa,b, Robert P. Ostrowskib,e, Anatol Manaenkob, Kamil
Durisb, John H. Zhangb,c,d, Jiping Tangb,d.
a

Department of Microbiology and Molecular Genetics, b Department of Physiology and
Pharmacology, c Department of Neurosurgery, d Department of Anesthesiology, Loma
Linda University School of Medicine, Loma Linda, CA, 92354, USA, e Department of
Experimental and Clinical Neuropathology, Medical Research Centre, Polish Academy
of Sciences, 02-106 Warsaw, Poland
Corresponding Author: Jiping Tang, MD
Department of Physiology and Pharmacology
Loma Linda University School of Medicine
Risley Hall, Room 214
Loma Linda, CA, 92350, USA
Phone: (909) 558-7693
Fax: (909) 558-0119
Email: jtang@llu.edu, jipingtang@yahoo.com

This study was partially supported by National Institutes of Health grants NS060936 and
NS054685
The work presented in this chapter has been published,
Charles MS, Ostrowski RP, Manaenko A, Duris K, Zhang JH, Tang J. Role of the
pituitary-adrenal axis in granulocyte-colony stimulating factor-induced neuroprotection
against hypoxia-ischemia in neonatal rats. Neurobiol Dis. 2012.
http://dx.doi.org/10.1016/j.nbd.2012.03.021,

18

Abstract
Several reports indicate that the activity of the hypothalamic-pituitary-adrenal
axis (HPA) is increased after a brain insult and that its down-regulation can improve
detrimental outcomes associated with ischemic brain injuries. Granulocyte-colony
stimulating factor (G-CSF) is a neuroprotective drug shown in the naïve rat to regulate
hormones of the HPA axis. In this study we investigate whether G-CSF confers its
neuroprotective properties by influencing the HPA response after neonatal hypoxiaischemia (HI). Following the Rice-Vannucci model, seven-day old rats (P7) were
subjected to unilateral carotid ligation followed by 2.5 hours of hypoxia. To test our
hypothesis, metyrapone was administered to inhibit the release of rodent specific
glucocorticoid, corticosterone, at the adrenal level. Dexamethasone, a synthetic
glucocorticoid, was administered to agonize the effects of corticosterone. Our results
show that both G-CSF and metyrapone significantly reduced infarct volume while
dexamethasone treatment did not reduce infarct size even when combined with G-CSF.
The protective effects of G-CSF do not include blood brain barrier preservation as
suggested by the brain edema results. G-CSF did not affect the pituitary released
adrenocorticotropic hormone (ACTH) levels in the blood plasma at 4 hours, but
suppressed the increase of corticosterone in the blood. The administration of G-CSF and
metyrapone increased weight gain, and significantly reduced the Bax/Bcl-2 ratio in the
brain while dexamethasone reversed the effects of G-CSF. The combination of G-CSF
and metyrapone significantly decreased caspase-3 protein levels in the brain, and the
effect was antagonized by dexamethasone. We report that G-CSF is neuroprotective in
neonatal HI by reducing infarct volume, by suppressing the HI-induced increase of the
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Bax/Bcl-2 ratio, and by decreasing corticosterone in the blood. Metyrapone was able to
confer similar neuroprotection as G-CSF while dexamethasone reversed the effects of GCSF. In conclusion, we show that decreasing HPA axis activity is neuroprotective after
neonatal HI, which can be conferred by administering G-CSF.

Introduction
Neonatal hypoxia ischemia (HI) remains the leading cause of perinatal brain
injury, which ultimately leads to cerebral palsy, mental retardation, and epilepsy
(Vannucci et al, 1999). It is a major public health concern with a prevalence of 60% in
preterm infants and an incidence of 1-8 cases per 1000 births (Vannucci, 2000). In spite
of its critical mortality and morbidity rate, current therapeutic avenues are still lacking;
thus necessitating alternative strategies to amplify current therapeutic potential.
Several reports suggest that the activity of the hypothalamic-pituitary adrenal (HPA) axis
is increased after HI, and that its down-regulation can reduce brain damage (Krugers et
al, 1998, Krugers et al, 2000). HPA axis activation involves the upregulation of the
adrenocorticotropic hormone (ACTH) and glucocorticoids. ACTH is released from the
pituitary gland in the blood stream where it acts on the adrenal glands to induce synthesis
and release of glucocorticoids. Glucocorticoids are reported to play an important role in
neurological function (Sorrells et al, 2009; Dumas et al, 2010), and neuronal damage in
the hippocampus after ischemic insults (Roy and Sapolsky, 2003). Studies have shown
that supraphysiological levels of glucocorticoids can exacerbate excitotoxic effects
(Stein-Behrens et al, 1992), elevate levels of reactive oxygen species (McIntosh and
Sapolsky, 1996), and increase neuroinflammation and apoptosis (MacPherson et al, 2005;
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Kuchinsky and Gillardon, 2000). This is of clinical relevance, since synthetic
glucocorticoids are often administered systemically in premature infants (Thébaud et al,
2001). Clinical studies have shown that premature infants treated with synthetic
glucocorticoids have reduced cerebral cortical grey matter volume (Murphy et al, 2001),
and impaired long-term neuromotor and cognitive function (Yeh et al, 2004).
Accordingly, targeting the HI induced elevation of glucocorticoids may be a promising
therapeutic target.
A promising stroke drug candidate, granulocyte-colony stimulating factor (GCSF), has been shown to modulate ACTH and glucocorticoids in rats (Mucha et al,
2000). G-CSF is a glycoprotein, and a growth factor known to confer neuroprotection in
various models of brain injury (Yata et al, 2007; Popa-Wagner et al, 2010). It is currently
in Phase II clinical trial for adult ischemic stroke, and well tolerated at high doses
(Schäbitz et al, 2010). In various animal studies, G-CSF has been reported to have antiapoptotic, anti-inflammatory, excitoprotective, and neurotropic properties (Solaroglu et
al, 2006, Gibson et al, 2005; Schäbitz et al, 2003; Konishi et al 1993). Furthermore, it has
shown promise in neonatal HI studies where it protected neurons from apoptosis, and
improved long term neurobehavior outcome (Yata et al, 2007; Fathali et al, 2010). A
variety of intracellular cascades activated by G-CSF decrease apoptotic markers caspase3, Bax (Solaroglu et al, 2009); these intracellular cascades are also regulated by
glucocorticoids. Whether G-CSF confers its neuroprotective effects through the HPA axis
in neonatal HI has yet to be determined.
On the basis of these observations, we hypothesize that G-CSF attenuates
apoptosis partially by down-regulating the activity of the HPA axis. Herein we chose to
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focus on the pituitary-adrenal response by measuring ACTH and rodent specific
glucocorticoid, corticosterone. To test this hypothesis we used metyrapone, an inhibitor
of glucocorticoid synthesis, which suppresses circulating levels corticosterone.
Metyrapone reduces corticosterone production by inhibiting the 11-β hydroxylation of
11-deoxycorticosterone. In addition, we used dexamethasone, a synthetic glucocorticoid
that agonizes the effects of circulating corticosterone. Here we investigate whether GCSF reduces neuronal apoptosis partially by regulating the ACTH and corticosterone
response following experimental neonatal HI.

Materials and Methods
Animal Model
The Institutional Animal Care and Use Committee of Loma Linda University
approved all the experiments used in this study. A modified Rice-Vannucci model was
used as previously described (Rice et al, 1981; Chen et al, 2009). In brief, SpragueDawley 7-day old rat pups (P7) underwent unilateral right common carotid ligation under
isoflurane anesthesia at 0300 hours. Because P7 rats do not have an established diurnal
rhythm of plasma corticosterone or ACTH, (Allen and Kendall, 1966; Leal et al, 1999)
we chose a time that was in the dark cycle consistent with the nocturnal activities of rats
(Levin and Levine, 1975). For consistent hormonal results, the ordered animals were
allowed 3 days to acclimate to the new facility and the surgeries were all conducted at the
same time. After recovery for 1 hour, the animals were placed in a hypoxic chamber
submerged in a 37oC water bath, subjected to 8% O2 balanced in N2 for 2.5 hours. Sham
animals underwent anesthesia and neck incision, the carotid was exposed without the
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ligation and was exposed to normoxic conditions. All P7 rats were returned to their
mothers at the same time after hypoxic exposure.

Drug Administration
A total of two hundred and fourteen animals were used in this study. Sixteen
animals expired in the hypoxic chamber giving this study a mortality of 7.47 percent. The
remaining one hundred and ninety-eight animals were randomly divided into the
following groups: Sham (n=24), Vehicle (n=27), G-CSF 50 µg/kg (n=29), Metyrapone 10
mg/kg (n=8), Metyrapone 30 mg/kg (n=29), G-CSF + Metyrapone 30 mg/kg (n=27),
Dexamethasone 0.1 mg/kg (n=7), Dexamethasone 0.5 mg/kg (n=23), G-CSF +
Dexamethasone 0.5 mg/kg (n=24). The drugs were administered subcutaneously in a total
volume of 30 µL one hour after hypoxia.

Blood and Collection
Blood was sampled 3 hours after drug administration and 24 hours after HI.
Briefly the animals were deeply anesthetized with isoflurane, and the blood was collected
via cardiac puncture with a 22-gauge needle. Blood was transferred in EDTA coated
tubes, and centrifuged at 3,000 rpm for 5 minutes. Blood plasma was immediately
removed and stored at -80oC until assayed (Mucha et al, 2000).

Infarct Volume and Body Weight
At 24 hours, brains were collected and infarct volume was determined with 2,3,5triphenyltetrazoliumchloride monohydrate (TTC) (Sigma Aldrich, St-Louis, MO USA)
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staining and analyzed by Image J software as previously described (Zhou et al, 2009).
Briefly, the brains were sectioned in 2 mm slices, incubated in 2% TTC solution for 5
minutes in the dark, washed in phosphate buffered saline (PBS), and fixed in 10%
formaldehyde. The infarct volume was traced and analyzed with Image J Software
(Version 1.43u; National Institutes of Health, Bethesda, MD, USA). The animals were
weighed on a high precision balance before surgery and at 24 hours immediately before
being euthanized. The weight difference was calculated as (weight 24 hrs after HI –
weight before surgery).

Brain Water Content
Pups were euthanized 24 hours after HI and the brains were divided in three parts
(ipsilateral and contralateral hemispheres, and cerebellum). Each part was immediately
weighed (wet weight) on a high precision balance (Denver Instrument, sensitivity ±
0.001 g) and again after drying in a 100oC oven for 24 hours (dry weight) as previously
described (Chen et al, 2008). The percentage was calculated as [(wet weight-dry
weight)/wet weight] x 100.

Hormone Assay
ACTH was measured with a two-site enzyme-linked immunosorbent assay
(ELISA) kit (MD Bioproducts, St.-Paul, MN, USA) following the manufacturer’s
protocol. This assay used a goat polyclonal antibody to ACTH, and a mouse monoclonal
antibody to ACTH that respectively bound the C-terminal (34-39) and the N-terminal of
ACTH (1-24). The minimum detection limit of the assay was 0.22 pg/mL.
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Corticosterone was measured with an ELISA kit (Enzo Life Sciences, Plymouth Meeting,
PA, USA) with a sensitivity of 27.0 pg/ml according to the manufacturer’s instructions.

Western Blot
Animals were euthanized at 24 hours after HI. The brain hemispheres were
immediately collected and snap frozen in liquid nitrogen and stored at -80oC until
analyzed. Whole cell protein extracts were obtained from brain samples by homogenizing
in RIPA lysis buffer (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) and
centrifuging for 25 minutes in 4oC at 14,000 g. Ten percent SDS-PAGE gels were used,
and 50 mg of denatured protein extracts were loaded in each well. The gel was
electrophoresed and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA,
USA). The membrane was blocked with 5% non-fat blocking grade milk (Bio-Rad) and
probed with appropriate dilution of primary antibody overnight. The following primary
antibodies used were: cleaved caspase-3 (Santa Cruz Biotechnology, 1: 1000), Bax (Cell
Signaling Technology, Danvers, MA, USA, 1:1000), Bcl-2 (Cell Signaling Technology,
1:1000), and actin (Santa Cruz Biotechnology, 1:1000). After washing the membranes
three times, they were probed with specie-specific secondary antibodies (Santa Cruz
Biotechnology) at 1:1000 dilutions for 1 hour at room temperature and visualized using
ECL Plus, Chemiluminescence (GE Healthcare and Life Sciences, Piscataway, NJ). The
optical densities of the bands were analyzed with Image J Software (Version 1.43u;
National Institutes of Health, Bethesda, MD) and normalized to actin as the loading
control.
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Statistical Analysis
The results are presented as the mean ± standard error mean (SEM). Statistical
differences among groups were analyzed by using one-way analysis of variance
(ANOVA) followed by the Tukey multiple comparison test (Graph Pad Prism Version
5.0d). Probability value<0.05 was considered statistically significant.

Results
Determining the Optimal Dose of Metyrapone and Dexamethasone
The metyrapone clinical dose for adrenal insufficiency is 30 mg/kg (Giordano et
al, 2008) hence the starting dose of choice. We used two doses 10 mg/kg and 30 mg/kg to
determine which dose would optimally reduce infarct volume compared to the control
groups. Dexamethasone on the other hand has previously been studied in neonatal HI
using the two following doses: 0.1 mg/kg and 0.5 mg/kg (Tuor et al, 1993, Ikeda et al,
2002). However, these reports use dexamethasone as pretreatment, our study will use it as
post-treatment. Our infarct volume results indicate that metyrapone reduces the infarct
volume in a dose dependent manner and the effect is significant with the 30 mg/kg
dosage (Figure 2.1). The vehicle group has a mean of 29.42% ± 3.40 and metyrapone 30
mg/kg significantly reduced the infarct percentage to 16.08% ± 2.57 (p<0.01vs HI
+Vehicle). The administration of dexamethasone did not significantly reduce infarct
volume when compared to vehicle; low dose (0.1 mg/kg) mean infarct percentage was
23.99% ± 1.25 and high dose (0.5 mg/kg) was 27.69% ± 1.69 (Figure 2.1).
Dexamethasone 0.5 mg/kg produced a significantly larger infarct volume compared to
that produced by metyrapone 30 mg/kg treatment (p<0.05) (Figure 2.1). Based on these
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Figure 2.1 Dose responses of metyrapone and dexamethasone. Representative
TTC stained coronal brain section of the dose response analysis for metyrapone
(MET) and dexamethasone (DEX) at 24 h. (* = p < 0.01 vs Vehicle, # = p < 0.05 vs
MET 30 mg/kg, all HI groups p < 0.01 vs Sham). Each line on the left hand side of
the brain images demarks 1 mm.
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results metyrapone 30 mg/kg and dexamethasone 0.5 mg/kg were considered as the
appropriate dosages for all the following experiments and molecular studies. The F value
for the ANOVA analysis conducted is 22.36.

Infarct Volume and Body Weight after G-CSF, Metyrapone
and Dexamethasone Administration
The administration of G-CSF (50 mg/kg) 1 hour after HI was able to significantly
reduce infarct percentage at 24 hours from 29.42% ± 3.40 to 14.70% ± 3.63 (p<0.05 vs.
HI + Vehicle, Figure 2.2A). Metyrapone (30 mg/kg) and the Metyrapone + G-CSF
groups similarly conferred neuroprotection by significantly reducing infarct volume
compared to the Vehicle group to 16.08% ± 2.57 and 15.08% ± 3.47 respectively (p<0.05
vs. HI + Vehicle). Furthermore, agonizing the HPA axis with dexamethasone (0.5 mg/kg)
administration did not significantly affect infarct volume compared to the Vehicle group
(27.69% ± 1.69 infarct percentage) and G-CSF lost its neuroprotective effect when coadministered with dexamethasone yielding an infarct percentage of 26.36% ± 2.78
(Figure 2.2A).
Since a characteristic of HI injury is weight loss (Chen et al, 2011), the weight
difference at 24 hours after HI was measured. The sham animals gained a mean weight of
2.11 g ± 0.22 after 24 hours while the HI vehicle treated pups lost an average 0.78 g ±
0.42. The animals treated with G-CSF lost 0.63 g ± 0.49 and the group treated with
metyrapone lost 1.07 g ± 0.26 which were not significantly different compared to the
vehicle treated group. Co-administration of G-CSF and metyrapone significantly reversed
the weight loss compared to all the other HI groups, the animals gained 1.25 g ± 0.39
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Figure 2.2 Infarct volume and body weight at 24 h after G-CSF, metyrapone and
dexamethasone administration. A. TTC stained coronal brain section of Sham, and GCSF, MET, DEX treated groups after HI. (* = p < 0.05 vs Vehicle, # = p < 0.05 vs GCSF, all HI groups p < 0.01 vs Sham). B. Body weight gain was measured on a high
precision balance scale and calculated as such: (Weight 24 h post-HI) − (Weight before
HI). (* = p < 0.01 vs Vehicle, # = p < 0.05, ** = p < 0.001 vs Sham, ## = p < 0.01 vs
MET + G-CSF). Each line on the left hand side of the brain images demarks 1 mm
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(P<0.01, Figure 2.2B). The administration of dexamethasone significantly exacerbated
weight loss compared to vehicle treated group by losing a mean 2.73 g ± 0.23 (p<0.01,
Figure 2.2B). Even when co-administered with G-CSF, the animals lost a mean of 2.14 g
± 0.42 (Figure 2.2B). All the groups that underwent HI significantly lost weight
compared to Sham group (p<0.001) except for the HI + G-CSF + Metyrapone group.

Measuring the Effect of G-CSF, Metyrapone and
Dexamethasone on Brain Edema After HI
Brain edema was assessed by measuring brain water content, which was elevated
in the ipsilateral hemisphere of the Vehicle treated group compared to Sham (p<0.05)
(Figure 2.3). G-CSF did not significantly reduce brain edema, but was significantly
different than the dexamethasone treated group (p<0.01), which also had elevated brain
edema when compared to Sham (p<0.01). Dexamethasone increased brain water content
even when co-administered with G-CSF (p<0.05 vs. Sham). The administration of
metyrapone alone or in combination with G-CSF did not significantly alter brain water
content. No significant changes in the brain water content amongst all the groups were
observed in the contralateral hemisphere and the cerebellum (Figure 3).
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Figure 2.3. Brain water content after G-CSF, metyrapone, and dexamethasone
treatment after HI. Quantification of brain water content 24 h after HI in the
cerebellum, contralateral, and ipsilateral brain hemisphere. Brain water content was
markedly increased by HI + Vehicle, DEX and DEX + G-CSF treated groups.
(* = p < 0.05). No significance was observed in G-CSF, MET and MET + G-CSF. DEX
treated group had higher brain water content than the G-CSF treated group (## = p < 0.05
vs G-CSF). No significant difference was observed amongst the groups in the cerebellum
and contralateral hemisphere.

31

ACTH Blood Plasma Level 4 Hours and
24 Hours after HI
The ACTH level in the blood was increased after HI (p<0.05 vs. Sham), and
administering G-CSF did not influence ACTH levels (Figure 2.4A). The administration
of metyrapone increased ACTH levels, while dexamethasone significantly reduced it as a
result of both drugs interfering with the negative feedback mechanism of the HPA axis
(p<0.01) (Figure 2.4A). At 24 hours, no significant differences were observed amongst
all the groups (Fig 2.4B).

Corticosterone Blood Plasma Level 4 Hours and
24 Hours after HI
The levels of corticosterone in the blood significantly increased after HI, and the
administration of G-CSF reduced corticosterone (Figure 2.5A). Metyrapone reduced
corticosterone levels while the administration of dexamethasone alone or in combination
with G-CSF increased corticosterone levels 4 hours after HI. At 24 hours, corticosterone
levels decreased in all the groups. It must be noted, that the groups that had G-CSF in
their treatment regimen had lower corticosterone levels than their control groups (Figure
2.5B). The dexamethasone+G-CSF group had significantly lower corticosterone levels
than the dexamethasone treated group.
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Figure 2.4 ACTH blood plasma level 4 h and 24 h after HI. A. At 4 h, ACTH levels
were significantly increased by HI (* = p < 0.05 vs Sham). MET and MET + G-CSF
groups had markedly increased ACTH level compared to Vehicle (## = p < 0.05). DEX
and DEX + G-CSF had significantly decreased ACTH levels compared to MET and
MET + G-CSF groups (# = p < 0.01 vs MET 30 mg/kg, ** = p < 0.01 vs MET + G-CSF).
B. ACTH blood plasma level is normalized to Sham at 24 h after HI.
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Figure 2.5 Corticosterone blood plasma level 4 h and 24 h after HI. A. HI
considerably increases CORT levels and G-CSF robustly decreases CORT levels at 4 h (#
= p < 0.05 vs Sham, * = p < 0.01 vs Vehicle). MET + G-CSF decreased CORT compared
to Vehicle group while the DEX + G-CSF group increased CORT levels significantly (**
= p < 0.05). B. CORT levels remain higher in Vehicle and DEX treated groups (* =
p < 0.05 vs Sham). All groups with G-CSF in their regimen have lower CORT levels than
their control group (# = p < 0.05 vs DEX 0.5 mg/kg).
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Apoptotic Markers Expression in the
Brain After Treatment
The western blot results indicate that G-CSF reduced pro-apoptotic marker Bax
(Figure 2.6A), and increased Bcl-2 (Figure 2.6B) in the ipsilateral hemisphere, however
the data did not yield statistical significance. HI induced an increase in the Bax/Bcl-2
ratio (p<0.05); this ratio was significantly lowered by the treatment of G-CSF,
metyrapone and the combination of metyrapone and G-CSF (p<0.05) (Figure 2.6C). The
HI-induced increase of cleaved caspase-3 was significantly reduced by the combination
of G-CSF and metyrapone treatment. Dexamethasone and dexamethasone + G-CSF cotreatment further increased cleaved caspase-3 levels (p<0.05 vs. Sham, p<0.05 vs.
MET+G-CSF).
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Figure 2.6 The expression of apoptotic markers in the ipsilateral hemisphere 24 h
post-HI. A. HI increased Bax protein expression. No significant difference is reported
amongst all groups. B. Bcl-2 relative density normalized to actin is decreased by HI but
no significant difference is observed between groups. C. Bax/Bcl-2 ratio was
significantly increased by HI (# = p < 0.05 vs Sham). G-CSF, MET and MET + G-CSF
treated groups significantly reduced Bax/Bcl-2 ratio compared to Vehicle treated groups
(* = p < 0.05). D. Cleaved caspase-3 levels are markedly increased by HI (# = p < 0.05 vs
Sham), and relatively lowered by G-CSF and MET groups (no significance observed).
MET + G-CSF significantly decreased caspase-3 levels (* = p < 0.05 vs Vehicle), and
DEX + G-CSF group antagonized the effects (** = p < 0.05 vs MET + G-CSF).
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Discussion
In the present study, we show that targeting the elevation of corticosterone in the
blood with G-CSF and metyrapone can protect the neonatal brain from HI injury,
increase development, and reduce apoptosis. We also show that administering
dexamethasone after HI impairs development, and worsens apoptosis. These results
support the hypothesis that elevated corticosteroids are detrimental to the functioning and
recovery of neurons after an insult (Tombaugh and Sapolsky, 1992; McIntosh and
Sapolsky, 1996).
G-CSF reduced infarct volume 24 hours after HI, and metyrapone similarly
reduced infarct volume. When G-CSF was co-administered with metyrapone, no further
reduction on infarct size was observed. As metyrapone could not potentiate the lowering
effect of G-CSF on the infarct volume it may be probable that both G-CSF and
metyrapone share a common mechanism of neuroprotective action. However this remains
to be elucidated. We postulate that the combination of G-CSF+ metyrapone maximally
reduced the progression of HI in the penumbra where milder injury is sustained as
detected by TTC for that specific time point of 24 hours. Because HI injury is more
severe and necrotic at its core (Nakajima et al, 2000; Pulera et al, 1998), the necrotic cells
have been irreversibly damaged and are beyond rescue. The penumbra, the area
surrounding the ischemic core, is not exposed to the same intensity of energy failure;
these neurons are in a critical stage where they can be recovered. It is with that premise
that combined therapy, may have maximally rescued the cells in the penumbra but could
not reverse the damage caused at the core. Although no synergistic effect was observed in
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the infarct volume analysis, the animals treated with G-CSF and metyrapone gained
weight in comparison to all the other groups that were subjected to HI.
When the activity of corticosterone was agonized with dexamethasone no
difference in infarct volume was detected when compared to the Vehicle treated group.
The protection observed with G-CSF treatment was completely lost when combined with
dexamethasone. This result suggests G-CSF may also exert its protection through
lowering the corticosterone level. This data is of extreme importance since multiple
reports suggest that dexamethasone treatment is neuroprotective in HI studies (Feng et al,
2011; Ikeda et al, 2005; Felszeghy et al, 2004; Ekert et al, 1997; Tuor et al, 1996). In
those reports, dexamethasone was administered before inducing experimental HI. Since
most incidences of HI can occur in utero thus making the time occurrence difficult to
detect (Wörle et al, 1984; Perlman, 2006), the translatability of these findings are
extremely difficult. Especially since pretreatment would imply indentifying children who
are at risk for hypoxia ischemia, which is difficult to assess (Perlman, 2006; Butt et al,
2008). Additionally, a long-term study reports that preterm infants treated with
dexamethasone for bronchopulmonary dysplasia or chronic lung disease (Halliday et al,
2009) were at increased risk for cerebral palsy and adverse neurological effects, all of
which are outcomes caused by HI (Volpe, 2001; Vannucci et al, 2000). Although pretreatment of dexamethasone does reduce HI injury and facilitates extubation, (Tuor et al,
1995; Davis et al, 2000), it could be detrimental for proper neurological development in
preterm infants. Our results show that dexamethasone administration after HI does not
reduce infarct volume, and further exacerbates development as indicated by weight loss.
If G-CSF were to be administered clinically in a preterm child, the administration of
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dexamethasone may antagonize its effects. This postulate would require human studies to
be authenticated.
The occurrence of apoptosis prevails in the penumbra where milder injury has
been sustained after the HI insult (Pulera et al, 1998). Apoptosis peaks from 24-72 hours;
since its occurrence is delayed, it is an important and suitable target for treatment. Our
results show that the expression of apoptotic markers are influenced by the hormones
involved in the pituitary-adrenal response. The Bax/Bcl-2 ratio was significantly lowered
by the administration of metyrapone alone and G-CSF. Additionally, the combined GCSF + metyrapone treated group had significantly lower caspase-3 than G-CSF and
metyrapone alone. These results suggest that the synergistic effect of both drugs could be
attributed to other pathways all directed at lowering caspase-3. When dexamethasone was
administered, higher expression of caspase-3 was observed, thus inferring that the
progression of the disease is worsened by dexamethasone administration.
The pathophysiology of HI also involves an increased vascular permeability,
which leads to brain edema. It is well documented clinically that the administration of
corticosteroid can reduce brain edema (Betz et al, 1990 stroke; Heiss et al, 1996). The
integrity of the blood brain barrier is usually compromised within hours of ischemic
injuries (Zhang et al, 2000). Administering corticosteroid to target brain edema has been
shown to reduce the pathological sequelae involved in brain swelling (Fishman, 1982).
Our results however indicate that brain edema is significantly increased when
dexamethasone 0.5 mg/kg is administered. The contradiction of our results to what is
typically observed clinically could be due to the inverted-U shape dose effect curve of
corticosteroids (Baldi and Bucherelli, 2005). The non-linear effect of corticosteroids
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ought to be considered when interpreting our results. Understanding the exact dose
response of dexamethasone and treatment in neonatal hypoxia ischemia therapy for brain
edema is an area necessitating further studies. Also, whether targeting brain edema is
sufficient to reduce neuronal cell death in neonates is another area granting further
investigation. When it came to G-CSF and metyrapone, these drugs did not significantly
reduce brain edema. The interpretation of this data suggests that their mechanism of
action may not involve preserving blood brain barrier integrity.
It is clear that the pituitary-adrenal response is increased after HI, and that
modulating its effects may prove beneficial in reducing infarct volume in the acute phase
of injury. Considerable reports have shown that elevated plasma corticosterone can
exacerbate neuronal damage in adult brain injury models of HI (Krugers et al, 2000, Stein
and Sapolsky et al, 1988). Our results show that administering metyrapone reduced
corticosterone levels in neonates after HI, however the administration of G-CSF reduced
corticosterone levels more robustly as seen at the 4 hours time-point. At 24 hours, all the
animals that had G-CSF in their treatment regimen had lower corticosterone levels than
their control group. What is perplexing is that ACTH levels were not affected by the
administration of G-CSF. This implies that G-CSF signaling is able to either directly
affect steroidogenesis at the adrenal level, or decrease the free corticosterone in the blood
by increasing corticosteroid-binding protein in the blood. It can be argued that G-CSF
affects the pituitary-adrenal response as a by-standard effect of its capacity to reduce
injury (Yata et al, 2007) and thus reducing the stress on the animal. However, we oppose
this precept since G-CSF did not affect ACTH levels. Furthermore a previous report has
shown that G-CSF can modulate the pituitary-adrenal response in naïve rats (Mucha et al,

40

2000). The mechanism by which G-CSF affects corticosterone level after HI should be a
new area of interest to further understand its application clinically.
We conclude that reducing HI-induced corticosterone elevation with both G-CSF
and metyrapone reduces infarct volume, and pro-apoptotic markers. Additionally, the
nature of G-CSF neuroprotection may involve CORT suppression in the blood. We also
demonstrate that administering dexamethasone after HI exacerbated neuronal damage,
impaired development and apoptosis.

41

References
Allen C, Kendall JW. Maturation of the circadian rhythm of plasma corticosterone in the
rat. Endocrinology. 1967 May;80(5):926-30
Baldi E, Bucherelli C. The inverted "u-shaped" dose-effect relationships in learning and
memory: modulation of arousal and consolidation. Nonlinearity BiolToxicol
Med. 2005 Jan;3(1):9-21
Betz AL, Coester HC. Effect of steroids on edema and sodium uptake of the brain during
focal ischemia in rats. Stroke. 1990 Aug;21(8):1199-204
Butt TK, Farooqui R, Khan MA. Risk factors for hypoxic ischemic encephalopathy in
children. J Coll Physicians Surg Pak. 2008 Jul;18(7):428-32
Chen W, Jadhav V, Tang J, Zhang JH. HIF-1alpha inhibition ameliorates neonatal brain
injury in a rat pup hypoxic-ischemic model. Neurobiol Dis. 2008
Sep;31(3):433-41
Davis PG, Henderson-Smart DJ. Intravenous dexamethasone for extubation of newborn
infants. Cochrane Database Syst Rev. 2000;(2):CD000308. Review. Update in:
Cochrane Database Syst Rev. 2001;(4):CD000308
Dumas TC, Gillette T, Ferguson D, Hamilton K, Sapolsky RM. Anti-glucocorticoid gene
therapy reverses the impairing effects of elevated corticosterone on spatial
memory, hippocampal neuronal excitability, and synaptic plasticity. J Neurosci.
2010 Feb 3;30(5):1712-20
Ekert P, MacLusky N, Luo XP, Lehotay DC, Smith B, Post M, Tanswell AK.
Dexamethasone prevents apoptosis in a neonatal rat model of hypoxic-ischemic
encephalopathy (HIE) by a reactive oxygen species-independent mechanism.
Brain Res. 1997 Jan 30;747(1):9-17
Fathali N, Lekic T, Zhang JH, Tang J. Long-term evaluation of granulocyte-colony
stimulating factor on hypoxic-ischemic brain damage in infant rats. Intensive
Care Med. 2010 Sep;36(9):1602-8
Felszeghy K, Banisadr G, Rostène W, Nyakas C, Haour F. Dexamethasone down
regulates chemokine receptor CXCR4 and exerts neuroprotection against
hypoxia/ischemia-induced brain injury in neonatal rats.
Neuroimmunomodulation. 2004;11(6):404-13
Feng Y, Rhodes PG, Bhatt AJ. Dexamethasone pre-treatment protects brain against
hypoxic-ischemic injury partially through up-regulation of vascular endothelial
growth factor A in neonatal rats. Neuroscience. 2011 Apr 14;179:223-32

42

Fishman RA. Steroids in the treatment of brain edema. N Engl J Med. 1982 Feb
11;306(6):359-60
Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-CSF suppresses edema
formation and reduces interleukin-1beta expression after cerebral ischemia in
mice. J Neuropathol Exp Neurol. 2005 Sep;64(9):763-9
Giordano R, Picu A, Bonelli L, Balbo M, Berardelli R, Marinazzo E, Corneli G, Ghigo
E, Arvat E. Hypothalamus-pituitary-adrenal axis evaluation in patients with
hypothalamo-pituitary disorders: comparison of different provocative tests.
ClinEndocrinol (Oxf). 2008 Jun;68(6):935-41
Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for
preventing chronic lung disease in preterm infants. Cochrane Database Syst
Rev. 2009 Jan 21;(1):CD001146
Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, Edwards
NA, Oldfield EH. Mechanism of dexamethasone suppression of brain tumorassociated vascular permeability in rats. Involvement of the glucocorticoid
receptor and vascular permeability factor. J Clin Invest. 1996 Sep
15;98(6):1400-8
Ikeda T, Mishima K, Aoo N, Liu AX, Egashira N, Iwasaki K, Fujiwara M, Ikenoue T.
Dexamethasone prevents long-lasting learning impairment following a
combination of lipopolysaccharide and hypoxia-ischemia in neonatal rats. Am J
Obstet Gynecol. 2005 Mar;192(3):719-26
Ikeda T, Mishima K, Yoshikawa T, Iwasaki K, Fujiwara M, Xia YX, Ikenoue T.
Dexamethasone prevents long-lasting learning impairment following neonatal
hypoxic-ischemic brain insult in rats. Behav Brain Res. 2002 Oct
17;136(1):161-70
Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin
and other hematopoietic factors on central cholinergic neurons in vitro and in
vivo. Brain Res. 1993 Apr 23;609(1-2):29-35
Krugers HJ, Kemper RH, Korf J, Ter Horst GJ, Knollema S. Metyrapone reduces rat
brain damage and seizures after hypoxia-ischemia: an effect independent of
modulation of plasma corticosterone levels? J Cereb Blood Flow Metab. 18
(1998) (4):386-90
Krugers HJ, Maslam S, Korf J, Joëls M, Holsboer F. The corticosterone synthesis
inhibitor metyrapone prevents hypoxia/ischemia-induced loss of synaptic
function in the rat hippocampus. Stroke. 31 (2000)(5):1162-72

43

Kuschinsky W, Gillardon F. Apoptosis and cerebral ischemia. Cerebrovasc Dis. 2000
May-Jun;10(3):165-9
Leal AM, Carvalho J, Moreira AC. Ontogenetic diurnal variation of adrenal
responsiveness to ACTH and stress in rats. Horm Res. 1999;52(1):25-9
Levin R, Levine S. Development of circadian periodicity in base and stress levels of
corticosterone. Am J Physiol. 1975 Nov;229(5):1397-9
MacPherson A, Dinkel K, Sapolsky R. Glucocorticoids worsen excitotoxin-induced
expression of pro-inflammatory cytokines in hippocampal cultures. Exp Neurol.
2005 Aug;194(2):376-83
McIntosh LJ, Sapolsky RM. Glucocorticoids may enhance oxygen radical-mediated
neurotoxicity. Neurotoxicology. 1996 17(3-4):873-82
Mucha S, Zylińska K, Pisarek H, Komorowski J, Robak T, Korycka A, Stepień H.
Pituitary-adrenocortical responses to the chronic administration of granulocyte
colony-stimulating factor in rats. J Neuroimmunol. 2000 Jan 3;102(1):73-8
Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, Jolesz FA, Volpe
JJ. Impaired cerebral cortical gray matter growth after treatment with
dexamethasone for neonatal chronic lung disease. Pediatrics. 2001
Feb;107(2):217-21
Nakajima W, Ishida A, Lange MS, Gabrielson KL, Wilson MA, Martin LJ, Blue ME,
Johnston MV. Apoptosis has a prolonged role in the neurodegeneration after
hypoxic ischemia in the newborn rat. J Neurosci. 2000 Nov 1;20(21):7994-8004
Perlman JM. Summary proceedings from the neurology group on hypoxic-ischemic
encephalopathy. Pediatrics. 2006
Popa-Wagner A, Stöcker K, Balseanu AT, Rogalewski A, Diederich K, Minnerup J,
Margaritescu C, Schäbitz WR. Effects of granulocyte-colony stimulating factor
after stroke in aged rats. Stroke. 2010 May;41(5):1027-31
Pulera MR, Adams LM, Liu H, Santos DG, Nishimura RN, Yang F, Cole GM, Wasterlain
CG. Apoptosis in a neonatal rat model of cerebral hypoxia-ischemia. Stroke.
1998 Dec;29(12):2622-30
Rice JE 3rd, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic
brain damage in the rat. Ann Neurol. 1981 Feb;9(2):131-41
Roy M, Sapolsky RM. The exacerbation of hippocampal excitotoxicity by
glucocorticoids is not mediated by apoptosis. Neuroendocrinology. 2003
77(1):24-31

44

Schäbitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Schölzke MN,
Sommer C, Schwab S. Neuroprotective effect of granulocyte colony-stimulating
factor after focal cerebral ischemia. Stroke. 2003 Mar;34(3):745-51.
Schäbitz WR, Laage R, Vogt G, Koch W, Kollmar R, Schwab S, Schneider D, Hamann
GF, Rosenkranz M, Veltkamp R, Fiebach JB, Hacke W, Grotta JC, Fisher M,
Schneider A. AXIS: a trial of intravenous granulocyte colony-stimulating factor
in acute ischemic stroke. Stroke. 2010 Nov;41(11):2545-51
Solaroglu I, Cahill J, Tsubokawa T, Beskonakli E, Zhang JH. Granulocyte colonystimulating factor protects the brain against experimental stroke via inhibition of
apoptosis and inflammation. Neurol Res. 2009 Mar;31(2):167-72
Solaroglu I, Tsubokawa T, Cahill J, Zhang JH. Anti-apoptotic effect of granulocytecolony stimulating factor after focal cerebral ischemia in the rat. Neuroscience.
2006 Dec 28;143(4):965-74
Sorrells SF, Caso JR, Munhoz CD, Sapolsky RM. The stressed CNS: when
glucocorticoids aggravate inflammation. Neuron. 15 (2009) 64(1):33-9
Stein BA, Sapolsky RM. Chemical adrenalectomy reduces hippocampal damage induced
by kainic acid. Brain Res. 1988 Nov 8;473(1):175-80
Stein-Behrens BA, Elliott EM, Miller CA, Schilling JW, Newcombe R, Sapolsky RM.
Glucocorticoids exacerbate kainic acid-induced extracellular accumulation of
excitatory amino acids in the rat hippocampus. J Neurochem. 1992 58(5):17305
Thébaud B, Lacaze-Masmonteil T, Watterberg K. Postnatal glucocorticoids in very
preterm infants: "the good, the bad, and the ugly"? Pediatrics. 2001
Feb;107(2):413-5
Tombaugh GC, Sapolsky RM. Corticosterone accelerates hypoxia- and cyanide-induced
ATP loss in cultured hippocampalastrocytes. Brain Res. 1992 Aug
14;588(1):154-8
Tuor UI, Del Bigio MR. Protection against hypoxic-ischemic damage with corticosterone
and dexamethasone: inhibition of effect by a glucocorticoid antagonist RU38486.
Brain Res. 1996 Dec 16;743(1-2):258-62
Tuor UI, Simone CS, Barks JD, Post M. Dexamethasone prevents cerebral infarction
without affecting cerebral blood flow in neonatal rats. Stroke. 1993
Mar;24(3):452-7
Tuor UI. Dexamethasone and the prevention of neonatal hypoxic-ischemic brain damage.
Ann N Y Acad Sci. 1995 Sep 15;765:179-95

45

Vannucci RC, Connor JR, Mauger DT, Palmer C, Smith MB, Towfighi J, Vannucci SJ.
Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res. 55
(1999) (2):158-63
Vannucci RC. Hypoxic-ischemic encephalopathy. Am J Perinatol. 17(2000) (3):113-20
Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev
Disabil Res Rev. 2001;7(1):56-64
Wörle H, Versmold H. [Hypoxic-ischemic encephalopathy. Clinical considerations].
PadiatrPadol. 1984;19(4):355-64
Yata K, Matchett GA, Tsubokawa T, Tang J, Kanamaru K, Zhang JH. Granulocytecolony stimulating factor inhibits apoptotic neuron loss after neonatal hypoxiaischemia in rats. Brain Res. 2007 May 11;1145:227-38
Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school
age after postnatal dexamethasone therapy for lung disease of prematurity. N
Engl J Med. 2004 Mar 25;350(13):1304-13
Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M.
VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the
ischemic brain. J Clin Invest. 2000 Oct;106(7):829-38

46

CHAPTER THREE
GRANULOCYTE-COLONY STIMULATING FACTOR INHIBITS
CORTICOSTERONE SYNTHESIS VIA THE JAK2/PI3K/PDE PATHWAY IN Y1
ADRENAL CORTICAL CELLS BY MODULATING CYCLIC ADENOSINE
MONOSPHOSPHATE SIGNALING
Mélissa S. Charlesa,b, John H. Zhangb,c,d, Jiping Tangb,d.
a

Department of Microbiology and Molecular Genetics, b Department of Physiology and
Pharmacology, c Department of Neurosurgery, d Department of Anesthesiology, Loma
Linda University School of Medicine, Loma Linda, CA, 92354, USA

Corresponding Author: Jiping Tang, MD
Department of Physiology and Pharmacology
Loma Linda University School of Medicine
Risley Hall, Room 214
Loma Linda, CA, 92350, USA
Phone: (909) 558-7693
Fax: (909) 558-0119
Email: jtang@llu.edu, jipingtang@yahoo.com
This study was partially supported by National Institutes of Health grants NS060936 and
NS054685

47

Abstract
It has been reported that granulocyte-colony stimulating factor (G-CSF)
influences the activity of the hypothalamic-pituitary-adrenal (HPA) axis primarily via the
hormones adrecorticotropic hormone (ACTH) and glucocorticoids. Namely, G-CSF was
shown to inhibit corticosterone in rodents after a hypoxic-ischemic event; the rodent
specific glucocorticoid known to exacerbate injury after an insult. The manner in which
G-CSF interacts with corticosterone biosynthesis remains to be examined. In this study,
we investigate for the first time the underlying mechanism of G-CSF on corticosterone
biosynthesis in a rodent Y1 adrenal cortical cell line. Cholera toxin was used to agonize
corticosterone synthesis by constitutively increasing cyclic adenosine monophosphate
(cAMP). Corticosterone and cAMP were quantitatively assayed using a commercial
enzyme-linked immunosorbent assay (ELISA). Janus Kinase 2
(JAK2)/Phosphatidylinositol-3-kinases (PI3K)/Protein kinase B (Akt), the downstream
signaling components of G-CSF receptor activation, their phosphorylated forms and
Phosphodiesterase 3B (PDE3B) were detected by western blot. G-CSF at a low dose (30
ng/ml) inhibited corticosterone synthesis, but lost its inhibitory effect as you increased its
concentration. The inhibitory effect of G-CSF was conferred by interfering with the
cAMP signaling via the activation of JAK2/PI3K/PDE3B pathway, as verified with
respective inhibitors. The degradation of cAMP by G-CSF signaling reduced
corticosterone. We conclude that G-CSF mediates corticosterone synthesis inhibition at
the adrenal level via JAK2 activation ultimately degrading intracellular cAMP in Y1
cells.
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Introduction
Previous reports indicate that G-CSF, a neuroprotective and hematopoietic
protein, may be involved in regulating hormones of the hypothalamic-pituitary-adrenal
(HPA) axis, primarily adrenocorticotropic hormone (ACTH) and the rodent specific
glucocorticoid, corticosterone (Mucha et al, 2000; Charles et al, 2012). The paucity of
studies investigating the effect of hematopoietic growth factors on neuroendocrine
activity highlights an important area that necessitates investigation (Zylińska et al, 1999;
Tringali et al, 2007). Particularly in light of devastating clinical conditions that increase
HPA activity such as a cerebrovascular event (Charles et al, 2012; Weidenfeld et al,
2011; Krugers et al, 2000; Fassbender et al, 1994). Understanding how G-CSF influences
HPA activity may become a beneficial area of study, particularly when it can
downregulate the detrimental HPA activity reported in a rodent hypoxia-ischemia
neuronal injury model (Charles et al, 2012).
The results from the previous reports suggest a probable relation and interaction
between G-CSF and the organs of the HPA axis. Starting with the adrenal gland, no
studies have demonstrated the direct effect of G-CSF on the adrenal cells involved in
steroidogenesis. Furthermore, the expression of the G-CSF receptor on adrenal glands has
not previously been reported. However, there are other reports illustrating that other
ligands such as erythropoietin and leptin, that have similar downstream signaling
pathways as G-CSF, interact with the HPA axis (Roubos et al, 2012; Hsu et al, 2006;
Tringali et al, 2007; Tokgöz et al, 2002). The supposition that G-CSF may influence
corticosterone synthesis is highly probable since its receptor belongs to a long chain
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helical cytokine family whose ligands have shown to influence steroidogenesis (Hiroike
et al, 2000; Mashburn and Atkinson, 2008; Hsu et al, 2006). The Janus Kinase 2 (JAK2)/
phosphatidylinositol-3-kinases (PI3K)/ protein kinase B (Akt) signaling pathway has
been shown to inhibit steroidogenic products in cell culture models, and regulate
steroidogenic proteins transcription and translation (Lefrancois-Martinez et al, 2011; Li et
al, 2003; Hsu et al, 2006). In light of these observations, it is highly probable that G-CSF
may exert its steroidogenic influences similarly.
At the adrenal level, steroidogenesis occurs in adrenal cortical cells, and is
initiated by ACTH which increases the intracellular level of its second messenger cyclic
adenosine monophosphate (cAMP) (Rainey et al, 2004; Cooke, 1999). In the widely used
Y1 rodent adrenal cortical cell line, steroidogenesis can be initiated by any stimulant of
cAMP production such as cholera toxin (Forti et al, 2002; Yasumura et al, 1966). The
induction of cAMP production leads to the activation of protein kinase A (PKA)
ultimately leading to steroidogenesis (Lin et al, 1995; Lopez et al, 2001; Clark et al,
2000). Previous reports have shown that JAK2 activation can suppress steroidogenesis by
inhibiting its upstream regulator cAMP with phosphodiesterase 3B (PDE3B) (Hsu et al,
2006; Johnsen et al, 2009). Additionally, we have previously shown that G-CSF can
reduce corticosterone after neonatal hypoxia–ischemia (Charles et al, 2012). Whether GCSF influences the steroidogenic process initiated by cAMP through JAK2 activation in
an adrenal cell culture model has yet to be explored.
In light of these observations, we propose to study for the first time the effects of
G-CSF on steroidogenesis in Y1 adrenal cortical cells. We hypothesize that G-CSF
mediates corticosterone synthesis inhibition on Y1 cells by activating the
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JAK2/PI3K/Akt/PDE3B pathway. We will use cholera toxin to constitutively increase
cAMP production, and test our hypothesis by inhibiting the JAK2/PI3K/PDE3B pathway
with appropriate inhibitors. We will investigate the mechanistic effect of G-CSF on
cAMP and corticosterone production.

Material and Methods
Cell Culture
Rodent Y1 adrenal cortical cells (ATCC, Manassas, VA) were grown in F12K
medium (ATCC) supplemented with 2.5% fetal bovine serum (ATCC), 15% horse serum
(Fisher Scientific, St-Louis, MO), and 1% penicillin/streptomycin (Thermo Scientific,
Rockford, IL), as a monolayer in a humidified atmosphere at 37oC in 5% CO2 in T75
flasks (BD Biosciences, San Jose, CA). Medium was changed every 4 days, and cells
were sub-cultured after 8 days and split to a 1:3 ratio. The cells were stored in liquid
nitrogen (5% dimethyl sulfoxide (DMSO) growth medium) or plated for experiments. All
experiments were conducted in passage 4 - passage 6 cells. Cells were counted using the
TC10TM Automated Cell Counter (Bio-Rad Life Science, Hercules, CA) and seeded in 12
well plates at a concentration of 1 X 106 of live cells/well. The cells were grown in 2 ml
of growth media/well for 48 hours. The cells were immediately serum starved for 8 hours
as previously described (Calejman et al, 2011) and subsequently incubated with growth
medium for 24 hours containing the appropriate chemicals for the respective groups.
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Chemicals and Treatment
Cholera toxin, the JAK2 inhibitor Tyrphostin AG490 (AG490), the PI3K inhibitor
LY-294002, and the PD3B inhibitor 3-isobutyl-1-methylxanthine (IBMX) were
purchased from Sigma-Aldrich (St. Louis, MO). The inhibitors AG490, LY-294002, and
IBMX were respectively diluted in DMSO for stock solutions of 1mg/ml, 5 mg/ml, and
0.5 M. G-CSF receptor chimera (Fc Chimera Active) was purchased from Abcam
(Cambridge, MA) and G-CSF was obtained from Loma Linda University Pharmacy. The
following concentrations were used: cholera toxin (50 ng/ml) (Hsu et al, 2006), AG490
(50 µM) (Chen et al, 2005), LY-294002 (20 µM) (Williams et al, 2010), IBMX (10 µM)
(Montero-Hadjadje et al, 2006). A dose response for G-CSF (30, 100, 300 ng/ml) (Hsu et
al, 2006) and the G-CSF receptor chimera (10, 30, 100 ng/ml) after cholera toxin
treatment was conducted. At 24 hours, growth media were collected from each well for
subsequent assay and analysis. G-CSF treated cells were collected at the following time
points after the initiation of treatment: 0, 5, 15, 30, 60, 120 minutes to determine the
activity of the JAK/PI3K/Akt/PDE3B pathway.

Cell Viability Assay
At 24 hours post-treatment, growth media were removed from each well and the
cells were trypsinized. Trypan Blue Cell Exclusion was used to determine cell viability
which was assayed and recorded using the TC10 Automated Cell Counter Cell Viability
analysis and protocol (Bio-Rad).
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Corticosterone and cAMP Quantitative Assay
Corticosterone was measured in the growth media 24 hours after treatment (Astort
et al, 2009, Calejman et al, 2010) using a commercial enzyme-linked immunosorbent
assay (ELISA) kit (Enzo Life Sciences, Farmingdale, NY). The minimum detection limit
of the assay was 27.0 pg/ml. A 1:20 dilution of the media was assayed according to the
manufacturer’s instructions. After 2 hours of treatment (Hsu et al, 2006), growth media
were removed and hydrochloric acid was added to the cells to stop the activity of
phosphodiesterases. The levels of cAMP were quantitatively analyzed using a
colorimetric competitive ELISA kit (Enzo Life Sciences) with a sensitivity of 0.30
pmol/ml.

Western Blot
Cells were washed with phosphate buffered saline (PBS) and incubated in 100 µl
of RIPA cell lysis buffer (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 20
minutes. Cells were snap-frozen in liquid nitrogen, thawed, and centrifuged at 125g for
10 minutes. The supernatant was collected, and assayed for protein concentration using
the spectroscopic Bradford protein Assay (Bio-Rad). Approximately 30 µg of proteins
were electrophoresed in 10% SDS-PAGE gel, and transferred on a nitrocellulose
membrane (Bio-Rad). The membrane was blocked with 5% non-fat blocking grade milk
(Bio-Rad) and probed with a 1:1000 dilution of primary antibody overnight. The
following antibodies were used: G-CSF receptor (Abcam), JAK-2 (Abcam), phosphorJAK2 (Abcam), PI3K (Cell Signaling Technology, Danvers, MA), phosphor-PI3K (Cell
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Signaling Technology), Akt (Cell Signaling Technology), phosphor-Akt (Cell Signaling
Technology), PDE3B (Abcam), and actin (Santa Cruz Biotechnology). After washing the
membranes three times, they were probed with a 1:1000 dilution secondary antibodies
(Santa Cruz Biotechnology) for the specie of the primary antibody for 1 hour at room
temperature. The protein bands were visualized with ECL Plus, Chemiluminescence (GE
Healthcare and Life Sciences, Piscataway, NJ). The densities were analyzed using Image
J Software (Version 1.43u; National Institutes of Health, Bethesda, MD) and normalized
to actin.

Statistical Analysis
The data are presented as the mean ± standard error mean (SEM). One-way
analysis of variance (ANOVA) followed by post-hoc Tukey multiple comparison test was
used. A probability value < 0.05 was considered statistically significant.

Results
G-CSF Influences Cholera Toxin-Induced Steroidogenesis via its
Own Receptor on Y1 cells
The expression of the G-CSF receptor has not previously been reported in adrenal
cells. Therefore, its expression was first investigated with western blot. Our results
indicate that the G-CSF receptor protein is expressed in Y1 cells (Figure 3.1A)
suggesting its function on adrenal cortical cells. The administration of cholera toxin
significantly (p<0.001) increased the steroidogenic product of corticosterone 5 times the
percentage of the vehicle group (Figure 3.1B). G-CSF administration with cholera toxin
inhibited corticosterone synthesis at the low dose of 30 ng/ml (p<0.05 vs. cholera toxin)
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but lost its inhibitory property as you increased the dose to 100 and 300 ng/ml (Figure
3.1B). The concentration of cholera toxin +G-CSF 300 ng/ml was significantly increased
compared to cholera toxin + G-CSF 30 ng/ml (p<0.05). To determine if G-CSF receptor
activation was responsible for the inhibitory effect observed on corticosterone synthesis,
the cells were incubated with cholera toxin + G-CSF + G-CSF Receptor Chimera (10, 30,
100 ng/ml). The inhibition of corticosterone synthesis was lost when the G-CSF receptor
chimera was added (Figure 3.1C). The inhibitory effect reached significance at 30 ng/mL.
In light of the objective of this study, G-CSF 30 ng/mL was used for subsequent
molecular assays and hormone analysis.
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G-CSF-R

Figure 3.1. G-CSF influences cholera toxin-induced steroidogenesis via its own
receptor on Y1 cells. A) G-CSF receptor is expressed in Y1 adrenal cortical cells. B) GCSF significantly inhibits cholera toxin (CTX)-induced synthesis of corticosterone at low
dose 30 ng/ml but loses its inhibitory property at 100 and 300 ng/ml. G-CSF 30 ng/ml
does not affect basal corticosterone synthesis. N=8/ group C) The addition of the G-CSF
receptor chimera reversed the inhibitory effect of G-CSF and reach significance at 100
ng/ml. #=p<0.01 vs Vehicle, * = p<0.05 vs CTX ** =p<0.05 vs CTX + G-CSF 30 ng/ml
N=6/group
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G-CSF Activates the JAK2/PI3K/Akt Pathway in Y1 cells
G-CSF receptor activation is known in other cell types to activate JAK2 and PI3K/Akt
downstream signaling (Nakamae-Akahori et al, 2006; Schneider et al, 2005). Whether
this is conserved in adrenal cells has yet to be determined. Accordingly, G-CSF (30
ng/ml) was administered and protein expression of JAK2, PI3K and Akt as well as their
phosphorylated active form were analyzed 0, 5, 15, 30, 60, 120 minutes after treatment
initiation. JAK2 phosphorylation increased over the time course as well as the total JAK2
protein (Figure 3.2A). The ratio of phosphor-JAK2/total JAK2 peaked at 60 minutes but
did not reach significance (Figure 3.2B). The increase of total JAK2 after G-CSF
treatment significantly peaked 30 minutes after treatment (p<0.05 vs. 0 minutes). The
protein expression of phosphor-PI3K increased over the time course and peaked 30
minutes after treatment (phosphor-PI3K/total PI3K) (p<0.05 vs. 0 minutes, Figure 3.2C).
Total PI3K protein expression remained constant (Figure 3.2D). The ratio of phosphorAkt/total Akt significantly increased and peaked 15 minutes post-treatment (P<0.05 vs. 0
minutes) (Figure 3.2E), while the total Akt protein expression remained constant (Figure
2F). PDE3B a downstream component of PI3K/Akt signaling was activated after G-CSF
treatment and increased 5 minutes after treatment (p<0.05 vs 0 minutes) (Figure 3.3.)
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Figure 3.2. G-CSF activates the JAK2/PI3K/Akt pathway in Y1 cells. A) & B)
Phophor-JAK2/total JAK2 in increased over the course of 120 minutes after G-CSF
treatment and peaks at 60 minutes. The total JAK2 protein expression is increased over
120 minutes and significantly peaks at 30 minutes (p<0.05 vs 0 minutes). C) & D)
Phosphor-PI3K/total PI3K peaks 30 minutes after G-CSF treatment (p<0.05 vs 0
minutes). Total PI3K expression is not affected by G-CSF treatment. E) & F) PhosphorAkt/total Akt protein activation is increased after G-CSF treatment and peaks at 15
minutes (p<0.05 vs 0 minute). Total Akt remains unchanged. N=4/group
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Figure 3.3. G-CSF activates PDE3B expression in Y1 cells. PDE3B is activated after
G-CSF 30 ng/ml treatment and significantly peaks 5 minutes after treatment (p<0.05 vs 0
minute). PDE3B levels decrease over time. N=4/group
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G-CSF Inhibits Corticosterone Synthesis via the
JAK2/PI3K/PDE3B Pathway
To determine whether JAK2/PI3K and the downstream element PDE3B is
involved in G-CSF inhibition of corticosterone synthesis, JAK2 inhibitor AG490, PI3K
inhibitor LY-294002 and PDE3B inhibitor IBMX were added to cholera toxin + G-CSF
30 ng/mL treatment. Additionally, since the inhibitors were dissolved in DMSO, a
control group DMSO (0.2%) was added for comparative analysis. DMSO 0.2% did not
increase corticosterone synthesis compared to control group. The addition of each
inhibitor in combination with cholera toxin + G-CSF 30 ng/ml to the media blunted the
inhibitory effect of G-CSF corticosterone synthesis (p<0.05 vs. cholera toxin + G-CSF 30
ng/mL) (Figure 3.4A). Corticosterone was significantly higher (p<0.05) in the media of
cells in the following groups compared to cholera toxin + G-CSF 30 ng/ml: cholera toxin,
cholera toxin + G-CSF 30 ng/mL + AG490, cholera toxin + G-CSF 30 ng/ml + LY294002, cholera toxin + G-CSF 30 ng/mL + IBMX. The administration of the drugs did
not significantly affect the cell viability as assessed with Trypan Blue Cell Exclusion
(Figure 3.4B)
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Figure 3.4. G-CSF inhibits corticosterone synthesis via the JAK2/PI3K/PDE
pathway. A) The JAK2 inhibitor (AG490), PI3K inhibitor (LY-294002), and PDE
inhibitor (IBMX) significantly reverse the corticosterone inhibition conferred by G-CSF
on cholera toxin-induced steroidogenesis (p<0.05 vs CTX + G-CSF 30 ng/ml). The
treatment with DMSO (0.2%), G-CSF 30 ng/ml, AG490, LY-294002, IBMX alone did
not significantly affect basal corticosterone synthesis compared to Control group. B)
Trypan Blue Cell Exclusion assay illustrates that the viability of each treated group is not
significantly different. N=6/group.
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G-CSF Inhibits Cholera Toxin-induced cAMP
Upregulation via JAK2/PI3K/PDE3B
The primary function of phosphodiesterases is to cleave the phosphodiester bond
of cAMP, the primary messenger and mediator of steroidogenesis (Mehats et al, 2002).
The measure of cAMP was assessed two hours after initiating treatment as previously
described (Hsu et al, 2006). Cholera toxin treatment increased cAMP significantly
compared to Control treated cells from 3.85 ± 0.20 pmol/L to 22.2 ± 2.84 pmol/ml
(p<0.01 vs. Control and DMSO) (Figure 3.5). G-CSF administration alone did not
significantly affect cAMP levels compared to Control and DMSO treated cells. The
combination of cholera toxin + G-CSF 30 ng/ml significantly reduced the cholera toxin
induced upregulation from 22.2 ± 2.84 pmol/mL to 14.47 ±0.60 pmol/mL (Figure 3.5).
The inhibition of JAK2 with AG490 in the cholera toxin + G-CSF 30 ng/ml + AG490
treated cells significantly antagonized the inhibitory effect of G-CSF (p<0.01 vs. cholera
toxin + G-CSF 30 ng/mL), the average concentration was 24.83 ± 2.60 pmol/mL.
Inhibiting PI3K with LY-294002 in the cells treated with cholera toxin + G-CSF 30
ng/ml yielded a cAMP level of 19.18 ± 1.38 pmol/mL; significantly higher than cells
without LY-294002 in the growth medium (p<0.01 vs. cholera toxin + G-CSF 30
ng/mL). The inhibition of PDE3B with IBMX substantively and significantly increased
cAMP levels in cells treated with cholera toxin + G-CSF to 61.15 ± 27.08 pmol/mL
(p<0.01 vs. cholera toxin + G-CSF 30 ng/mL). All the inhibitors reversed the G-CSF
reduction of cAMP levels in cholera toxin treated cells. Treatment with G-CSF 30
ng/mL and the inhibitors alone did not significantly change cAMP levels when compared
to control and DMSO treated cells.
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Figure 3.5. G-CSF abates cholera toxin-induced cAMP upregulation via the
JAK2/PI3K/PDE pathway. CTX significantly increased cAMP levels from 3.85 ± 0.20
pmol/l to 22.20 ± 2.84 pmol/ml (p<0.001 vs Control and DMSO (0.2%)). G-CSF
decreased the upregulation of cAMP to 14.47 ± 0.60 pmol/ml which was antagonized by
adding to the treatment the JAK2, PI3K, and PDE inhibitor (AG490, LY-294002,
IBMX). The treatment with DMSO (0.2%), G-CSF 30 ng/ml, AG490, LY-294002, and
IBMX alone did not significantly affect basal cAMP. N= 6/group.
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Discussion
In this current study we investigated for the first time the direct effect of G-CSF
on adrenal steroidogenesis and explored the probable mechanism by which G-CSFinduced inhibition of steroidogenesis. Thereupon we examined the involvement of GCSF in a well characterized rodent Y1 adrenal cortical cell line on steroidogenic
products. We show that G-CSF at 30 ng/mL inhibits cholera toxin induced corticosterone
synthesis and cAMP upregulation. We also report that the G-CSF receptor is expressed in
adrenal cortical cells and by co-administering G-CSF with its G-CSF receptor chimera
the inhibitory effect against cholera toxin is lost. Additionally, we demonstrate that GCSF activates the JAK2/PI3K/Akt/PDE3B pathway in adrenal cells which is responsible
for the inhibition of cAMP and steroidogenic signaling components and product hence
blunting corticosterone biosynthesis.
We first determined whether G-CSF receptor protein was expressed in the adrenal
cortical cells as no previous reports indicated the latter. Since our results show that the GCSF receptor was expressed, a dose response using G-CSF was conducted to determine
its influence on the glucocorticoid involved in HPA activity in rodent corticosterone. Our
results show that G-CSF inhibits corticosterone synthesis at low dose (30 ng/mL), but as
you increased the concentration the inhibitory effect was lost. We postulate that this
phenomenon is probably a result of non-genomic effects due to the saturation of the GCSF receptor. Hence other signaling pathways could be activated to oppose the inhibitory
effect or drive steroidogenesis. Based on the premise that increasing G-CSF
concentration reverses the inhibition, it is probable that increasing the concentration
beyond the ones used for this study could potentially increase steroidogenesis. This
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explanation would help reconcile the results of Mucha and colleagues (2000) indicating
that G-CSF increases corticosterone blood plasma level after chronic administration in
naïve rats. However, this remains to be elucidated.
The inhibitory effect of G-CSF was modulated by the activation of its receptor as
the addition of the G-CSF receptor chimera at various concentration resulted in an
increased corticosterone product (Figure 3.1C). For the first time, we show that G-CSF
has direct interaction with cells of an HPA organ. This is of critical importance primarily
if the effect can potentially cause adverse or beneficial therapeutic effects in a clinical
setting.
Since G-CSF is known to activate JAK2/PI3K/Akt in other tissues (NakamaeAkahori et al, 2006) and that PI3K/Akt is upstream to PDE3B, we measured the total and
activated forms of JAK2/PI3K/Akt and the expression of PDE3B over two hours after GCSF treatment initiation. Our results indicate that JAK2 phosphorylation increased over
two hours as did the total form of JAK2. Total JAK2 protein expression significantly
increased and peaked 30 minutes after treatment initiation. The activated forms of PI3K,
and Akt also increased over two hours peaking from 15-30 minutes, but unlike JAK2 the
total forms of PI3K and Akt expression were not affected. G-CSF also increased PDE3B
over the 120 minutes time course which peaked at 5 minutes. These results show that the
JAK2/PI3K/Akt activation of G-CSF is preserved in rodent adrenal cortical cells.
The corticosterone measurements indicate that G-CSF inhibits cholera toxin via
the JAK2/PI3K/PDE3B pathway since the addition of the inhibitors in the treatment
reversed its inhibitory effect. Therefore, this suggests that the pathway may be involved
in corticosterone synthesis inhibition. To verify that the differences reported amongst
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each treated groups were not due to cell viability, Trypan Blue Exclusion was used. The
results indicate that no significant difference was observed in cell viability amongst the
groups. Therefore, the observed effects in corticosterone synthesis and other molecular
events were attributed to the drugs influence on signaling pathways and not cell viability.
The elevation of cAMP observed two hours after the initiation of treatment with
cholera toxin was inhibited by G-CSF. This report suggests that the activation of
JAK2/PI3K/PD3B by G-CSF inhibits steroidogenesis by reducing cAMP levels.
Furthermore, the inhibitors of JAK2/PI3K/PDE3B individually reverse the inhibition of
cAMP levels. The levels of cAMP were further increased when treated with cholera toxin
+ G-CSF 30 ng/mL +IBMX compared to cells treated with cholera toxin alone. This
occurrence may be a result of inhibiting the basal levels of PDEs, which are activated by
steroidogenic signaling (Mehats et al, 2002). Steroidogenesis can initiate other signaling
pathways such as calcium signaling whose downstream event includes the activation of
PDEs (ibid). Therefore IBMX may inhibit the basal activity of PDEs, which would
attribute to the higher cAMP levels.
Concerning the limited studies that look at G-CSF and HPA activity, one in naïve
rats and one after hypoxia ischemia, one must understand the complexity of what is at
hand. Markedly, the putative ability of G-CSF to influence HPA activity ought to be
investigated also at the pituitary level and at the hypothalamic level. Reports have
indicated that other hematopoietic growth factors with similar signaling pathways can
inhibit corticotropin-releasing hormone (CRH) which is responsible for ACTH synthesis
at the pituitary level (Tringali et al, 2007; Zylińska et al, 1999). In light of our previous
report (Charles et al, 2012) indicating that ACTH was not increased in spite of
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corticosterone inhibition, one must consider the delicate negative feedback and the
probable interaction of G-CSF with the pituitary gland. This perplexing result puts in
question the negative feedback which should have shown an increase of ACTH as a result
of corticosterone inhibition. Therefore it is probable that G-CSF may have direct effects
on each organ of the HPA axis. Determining the manner in which G-CSF influences HPA
activity in a naïve model and after a diseased state merits further exploration.
In conclusion, we demonstrate that G-CSF has non-hematopoietic function in the
HPA axis by regulating steroidogenesis in the Y1 adrenal cortical cell line. G-CSF was
able to abate the upregulation of cholera toxin-induced cAMP via the
JAK2/PI3K/Akt/PDE3B pathway which ultimately inhibited the steroidogenic product of
corticosterone. We propose that a better understanding of the manner in which G-CSF
has neuroendocrine properties may better translate its efficacy in a clinical setting,
particularly when investigating diseases that involve the over-activation of the HPA axis.
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CHAPTER FOUR
DISCUSSION
How the activity of the HPA axis and its relation to G-CSF therapy reflect on
pathophysiological outcomes of HI was not previously investigated. For that reason, the
underlying foundation of this scientific initiative was to investigate the latter. We show
for the first time that the neuroprotective properties of G-CSF depend on its inhibition of
corticosterone synthesis. Furthermore, we demonstrate for the first time that G-CSF has
direct effects on steroidogenesis by activating its receptor on adrenal cortical cells. These
findings bifurcate our current knowledge of G-CSF function, similarly to when G-CSF
was first discovered to be neuroprotective.
G-CSF was first reported almost a decade ago, to have neuroprotective properties
in brain injury models such as stroke by activating its receptor in the central nervous
system (CNS) (Schäbitz et al, 2003; Gibson et al, 2005). It was joining the ranks of
another hematopoietic factor known to have modalities in the brain after injury,
erythropoietin (Masuda et al, 1993; Digicaylioglu et al, 1995). Subsequent studies that
emerged from this discovery have shed light on its multimodal properties that span across
a multitude of brain insults (Park et al, 2005; Ren and Finkelstein, 2005; Schneider et al,
2005). The numerous reports have indicated G-CSF as an angiogenic, neurogenic, antiinflammatory, and anti-apoptotic agent (Shyu et al, 2004; Gibson et al, 2005; KomineKobayashi et al, 2006; Schneider et al, 2005; Solaroglu et al, 2009, Strecker et al, 2010).
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Currently it is in Phase II clinical trial for adult ischemic injury where it is well tolerated
at high doses (Schäbitz et al, 2010). In addition to its promise in adult studies reflecting
similar injury as that seen in neonates, age appropriate animal models of HI also indicate
that G-CSF improves outcome after the insult (Yata et al, 2007, Fathali et al, 2010,
Charles et al, 2012). G-CSF was once unrecognized for its function in the CNS, and we
now show that its properties extend beyond its direct neuroprotective effects as illustrated
in stroke studies. Unknowingly, G-CSF had properties that influenced a very dynamic
and delicate neuroendocrine system, the HPA axis (Mucha et al, 2010).
There are numerous areas of HI pathophysiology that are still not investigated in
neonates as it pertains to HPA activity after a brain insult. However, indices can be
retrieved from other models indicating that high levels of glucocorticoids were associated
with poor outcome (Feibel et al, 1977; Krugers et al, 1998; Stein-Sapolsky, 1988). In the
adult HI injury model, results indicate that HPA overactivation in the acute phase was
detrimental and its down-regulation led to improved neurological outcome (Krugers et al,
2000; Smith-Swintosky et al, 1996). We measured for the first time the hormones of
ACTH and corticosterone in a neonatal HI model and indicated that G-CSF conferred its
properties by significantly decreasing corticosterone. Using metyrapone, the inhibitor or
corticosterone, and dexamethasone, a synthetic steroid that agonized the effects of
corticosterone, we showed that regulation of pituitary-adrenal activity is of critical
importance in G-CSF therapy. Especially since agonizing corticosterone led to impaired
development, and increased pro-apoptotic biomarkers even when co-administered with
G-CSF. Dexamethasone was administered after the insult, which was different from other
studies administering it hours prior to HI in neonates (Tuor et al, 1993; Ikeda et al, 2002).
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This difference yielded opposite effects. Pre-treatment with dexamethasone appears to be
protective, while our data show that post-treatment exacerbates injury. Why posttreatment of dexamethasone is detrimental in contrast to pre-treatment is an area that
remains to be elucidated; particularly when it comes to its co-administration with G-CSF.
This difference in pre and post-treatment could be owed to the intact versus disrupted
BBB, especially since dexamethasone does not cross an intact BBB. Hence its
exacerbation of injury could be attributed to its effect in CNS, while the protective effects
could be due to its impact in the periphery. This fact would need to be substantiated with
adequate HI studies. With attention to the hormone results, metyrapone and
dexamethasone show that the negative feedback in neonates in responsive. This finding
suggests that elements of the HPA axis are functional in the neonatal rat after HI. For this
reason, the suggestion that neonates have a hyporesponsive HPA axis needs to be
examined, particularly in the context of a cerebrovascular event (Tu et al, 2006). Overall,
the hormone data ultimately led to the question of how G-CSF inhibited corticosterone
synthesis? The analysis of the data immediately pointed towards G-CSF having a
probable direct interaction with the adrenal gland of the HPA axis.
The initial step was to determine whether the G-CSF receptor was expressed on
adrenal cortical cells. We identified for the first time the expression of the G-CSF
receptor on rodent adrenal cortical cells suggesting its direct effect on HPA activity. The
results we reported were perplexing as they were interesting. It was interesting since GCSF was shown to inhibit corticosterone synthesis. However this was true only at a low
dose. It became perplexing when at higher doses G-CSF lost its inhibitory properties. The
span of concentration that was utilized only covered so much ground. Therefore, one
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must wonder, whether high doses of G-CSF could do the exact opposite? If this were the
case then the study of Mucha and colleagues would be explained (2000). Particularly
since they report that chronic administration of G-CSF increased ACTH and
corticosterone in naïve rodent models. Whether this is a matter of alternate signaling
pathways or saturation of G-CSF receptor activation remains to be investigated.
Understanding the mechanism of G-CSF signaling as it pertained to
corticosterone inhibition is primordial to establish how the two components interrelate.
Since the receptor was expressed on a different cell type, we verified whether the
JAK/PI3K/Akt signaling was conserved. Our data indicate that the pathway is preserved
in adrenal cortical cells, and that it is responsible for the inhibitory proponent of G-CSF
activity on corticosterone synthesis.

Clinical Significance
The current therapeutic avenues of HI are extremely limited. Only hypothermic
therapy has shown a confined amount of success (Koenisgberger et al, 2000). There is a
plethora of determining factors including a paucity of adequate mechanistic animal
studies that halt the progress of promising drugs in the clinical setting. The complexity of
this issue contributes to the grim prognosis of HI patients. These patients are primarily
premature infants, and since the development of premature babies differ from term
babies, our study utilized a model reflective of that population. Can G-CSF uphold the
promise that our animal studies suggest in the clinic? Perhaps. However one must
consider the multiple physiological and molecular mechanisms that are activated by GCSF. Particularly, when it comes to its inhibitory properties on steroidogenesis. Our
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results show that co-administering G-CSF with dexamethasone does not protect the brain
of the animal from injury (Charles et al, 2012). In fact, it worsened development and
apoptosis (ibid). Scientifically this supported our hypothesis, but it challenges the
translatability of G-CSF. Here is why. Preterm infants often have developmental, and
lung maturation complications which are clinically treated with synthetic glucocorticoids
(Davis et al, 2001). If G-CSF were studied in a human clinical trial, the co-administration
of synthetic glucocorticoid would impair its neuroprotective ability as our data suggest.
This devastating outcome could lead clinicians to prematurely overlook the promise of GCSF. This could lead to a misguided conclusion, when ultimately the synthetic
glucocorticoid commonly found in the treatment regimen of premature infants is what
diverged the action of G-CSF. This study shows that in the acute phase, synthetic
glucocorticoids are detrimental. This is substantiated by a longitudinal study in which
preterm infants were at increased risk for cerebral palsy and adverse neurological effects
when treated with synthetic glucocorticoids, all of which are outcomes caused by HI
(Volpe, 2001; Vannucci et al, 2000). Nonetheless, because G-CSF potentially could
increase glucocorticoid long-term, it could potentially facilitate extubation by
endogenously increasing glucocorticoids (Mucha et al, 2000). This remains to be verified
with animal and human studies.
G-CSF has an excellent safety record, and a well-known pharmacological profile
due to is clinical use for neutropenia and bone marrow harvesting (Schneider et al, 2005;
Neidhart et al, 1989; Morstyn et al, 1989). This advantage makes its translatability
propitious. Additionally, its multimodal properties suggest that it can target the multiple
facets of HI pathophysiological sequelae. Therefore, if it were to transition into clinical
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trial for preterm infants, it could potentially be promising. The only caveat would be to
consider the use of synthetic glucocorticoids to maximize the promise of G-CSF.

Future Directions
Our study focused on two general areas: the effect of G-CSF after HI on the
synthesis of pituitary-adrenal axis hormones, and the mechanism by which it confers its
effect. We approached the first part of our study by investigating the effect of G-CSF on
pituitary-adrenal hormones as it pertained to apoptosis. Since glucocorticoids can also
affect inflammation, and glutamate excitotoxicity after a neuronal insult, these areas
merit further exploration (Dinkel et al, 2003; Goodman et al, 1996). Also, our study only
investigated the effect of G-CSF in the acute phase. How chronic administration of GCSF affects the pituitary-adrenal axis hormones long-term needs to be explored. The
neurobehavioral outcomes, brain atrophy, angiogenesis, and neurogenesis should also be
evaluated at long-term time points; particularly as in regards to dexamethasone, and
metyrapone administration. Additionally, an adequate dose response for G-CSF and its
effect on corticosterone should be investigated. Especially since the in vitro studies show
that higher doses of G-CSF lost its inhibitory property. Not to mention, that a study using
higher dose of G-CSF (200 µg/kg) did not protect the brain from neonatal HI injury,
compared to our lower dose (50 µg/kg) (Schlager et al, 2011; Charles et al, 2012).
Determining how this occurs and whether this effect is dependent on corticosterone is
essential to harness the full therapeutic promise of G-CSF.
In addition to the neuroprotective effect of G-CSF, G-CSF influences the
hormones of the neuroendocrine system. Our study focused on the direct interaction of G-
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CSF on the adrenal gland of the HPA axis, but many other areas have yet to be
investigated. There are cues from other studies showing growth factors or hormones with
similar signaling cascade that exert effect of the HPA-axis. Therefore there is a high
probability that the actions of G-CSF extend beyond the adrenal gland. Perhaps G-CSF
controls the activity of the HPA axis at the level of the hypothalamus and/or the pituitary
gland. The details of this possible interaction should be considered for subsequent
studies.

Conclusion
G-CSF has pleiotropic physiological effects, and we demonstrate that its
neuroprotection is dependent on its direct interaction with the HPA axis. We show that
G-CSF inhibits corticosterone synthesis, and protect the neonatal rat brain from HI injury,
by reducing infarct volume and reducing pro-apoptotic markers. Agonizing the effects of
the HPA axis with a synthetic glucocorticoid exacerbated injury even when coadministered with G-CSF. This study highlighted a novel function of G-CSF, since it
inhibited the HI-induced upregulation of corticosterone. We found that the G-CSF
receptor was expressed on adrenal glands and conferred its inhibitory effect on
corticosterone synthesis by activating the JAK2 signaling pathway. Future studies are
needed to better understand the interaction with G-CSF and the HPA axis. Nevertheless,
the promising therapeutic potential of G-CSF should continue to be pursued in
subsequent preclinical stroke research.
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